WO2012024611A1 - Procédés de traitement de la sarcopénie et de la fragilité - Google Patents

Procédés de traitement de la sarcopénie et de la fragilité Download PDF

Info

Publication number
WO2012024611A1
WO2012024611A1 PCT/US2011/048465 US2011048465W WO2012024611A1 WO 2012024611 A1 WO2012024611 A1 WO 2012024611A1 US 2011048465 W US2011048465 W US 2011048465W WO 2012024611 A1 WO2012024611 A1 WO 2012024611A1
Authority
WO
WIPO (PCT)
Prior art keywords
beta
alanine
subject
muscle
frailty
Prior art date
Application number
PCT/US2011/048465
Other languages
English (en)
Inventor
Roger Harris
John Wise
Original Assignee
Natural Alternatives International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natural Alternatives International, Inc. filed Critical Natural Alternatives International, Inc.
Publication of WO2012024611A1 publication Critical patent/WO2012024611A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid

Definitions

  • kits for treating beta-alanine for the treatment of muscular disorders and for the improvement of muscle function.
  • methods for maintaining muscle strength and function e.g., in the elderly
  • reversal or prevention of frailty or age-related functional decline in the elderly reversal or prevention of sarcopenia
  • treatment of musculoskeletal impairment in the elderly e.g., in the elderly.
  • China's 65-and-older population is expected to triple by 2050 and the population of people 65 and over in India is expected to quadruple, with estimates that people 65 or older will constitute 20 percent or more of their population (Aulova, CBS News Political Hotsheet, Census Bureau, Older Population to Triple by 2050 (2009)).
  • sarcopenia This progressive decrease in skeletal muscle mass and strength is known as sarcopenia, and contributes to frailty and falls in the elderly.
  • Sarcopenia does not require an underlying disease for manifestation. Decrease in muscle use can result in muscle function loss and/or loss in muscle mass.
  • Sarcopenia has been correlated to functional impairment, disability, falls, frailty, and the loss of independence that increases with aging.
  • the etiology of sarcopenia includes decreased physical activity and can be accompanied by malnutrition or inadequate protein consumption. Loss of muscle function and mass can lead to age-related decline and the onset of frailty. Underlying symptoms of frailty include the progressive loss of robust function in multiple tissues and organ systems, and can lead to decreased muscular support of skeletal structure.
  • Sarcopenia is a progressive process that occurs throughout adult life, and depending on one's physical activity, by the time a person is over 75 years old, muscle mass may have declined by as much as 50% compared to the amount of muscle mass present in the early twenties. This reduction of muscle mass, in conjunction with loss of muscle functionality, is a significant factor in the development of frailty, which is accompanied by falls that lead to fractures and ultimately to morbidity and mortality.
  • Sarcopenia has been identified as a cause of age-related disability (Harris, J. Nutr. 127: 1004S-1006S (1997); Lexell, J. Gerontol. 50A: 11-16 (1995)). Sarcopenia is believed to be associated with metabolic, physiologic, and functional impairments and disability.
  • sarcopenia in a subject.
  • methods to prevent, treat, delay, mitigate and/or ameliorate the onset, advancement, severity and/or symptoms of sarcopenia in a subject are also provided.
  • beta-alanine is provided in an amount and over a period of time sufficient to prevent, treat, delay, mitigate and/or ameliorate the onset, advancement, severity and/or symptoms of sarcopenia and/or frailty in a subject.
  • the method includes administering to the subject a beta-alanine in an effective amount and for sufficient time to inhibit muscle catabolism and/or increasing muscle anabolism in the subject.
  • the methods also can include co-administering a protein and/or one or more essential amino acids.
  • the method includes administering to the subject a beta-alanine in an effective amount and for sufficient time to improve the muscle: fat ratio in the subject.
  • the methods can include co-administering a protein and/or one or more essential amino acids.
  • the methods also can include modifying the diet of the subject, such as by increasing protein intake and/or reducing high glycemic index carbohydrate intake.
  • the method includes administering to the subject a beta- alanine in an effective amount and for sufficient time to improve the gait of the subject.
  • the methods can result in an increased stride length, reduced stride frequency, reduced stance width variability or a combination thereof.
  • the method includes administering to the subject a beta-alanine in an effective amount and for sufficient time to improve the muscle
  • the methods can result in improvements in functionally important tasks, such as improved results in the timed get-up-and-go test, the timed stand test, the stair climb muscle power test, and improvements in balance, such as the one-leg balance test or improvements in one or more criteria of the Berg balance test.
  • methods of improving a Berg Balance test score in an elderly subject including administering to the subject a beta-alanine in an effective amount and for sufficient time to improve the Berg Balance test score of the subject compared to a baseline score prior to administration of the beta-alanine.
  • the Berg Balance test score is improved by at least +5, and can be improved by +6, +7, +8, +9, +10, +11, +12, +13, +14, +15 or more. In some methods, the score is improved to be in a range between 30 and 40 or between 40 and 50.
  • the age of the subject can be selected from between 40 and 70 years old or older, such as at least 40, or at least 50, or at least 55, or at least 60, or at least 65, or at least 70 years of age.
  • a subject is within a particular range of ages.
  • the subject can be selected from among (a) 40-50, (b) 50-60, (c) 60-70 and (d) greater than 70 years of age.
  • the subject may have suffered some loss of muscle mass, but may not suffer from a condition that interferes with acts of daily living and/or prevents the subject from living an independent life. In some embodiments, the subject has suffered some loss of muscle mass and suffers from a condition that interferes with acts of daily living and/or prevents the subject from living an independent life. In some methods, the subject exhibits one or more symptoms of sarcopenia. In some methods, the subject exhibits one or more symptoms of frailty.
  • the beta-alanine can be administered to the subject for any length of time effective to achieve a desired result.
  • the beta- alanine can be administered to the subject for any length of time effective to achieve an increase in the level of a beta-alanyl-histidine dipeptide, such as carnosine, anserine, and balenine or salts or alkyl derivatives of these, particularly carnosine, in a muscle tissue.
  • the beta-alanine can be administered to the subject for any length of time effective to increase the plasma levels of beta-alanine in a subject.
  • the beta-alanine can be administered over a period of time of between 1 week and 1 year.
  • the beta- alanine can be administered to the subject for at least 6, 8, 10, 12, 14, 16, 18 or 20 weeks.
  • the beta-alanine can be administered to the subject for 1 year or more.
  • the beta-alanine can be administered to the subject in any dosage effective to achieve a desired result.
  • the beta-alanine can be administered to the subject in any dosage effective to achieve an increase in the level of a beta-alanyl-histidine dipeptide, such as carnosine in a muscle tissue.
  • the beta-alanine can be administered to the subject in any dosage effective to increase the plasma levels of beta- alanine in a subject.
  • the beta-alanine can be administered in a dose of between 0.1 g and 16 g per day.
  • the beta-alanine can be administered as a dosage of 200 mg, 400 mg, 600 mg, 800 mg, 1,000 mg or 1,200 mg, 1,400 mg, 1,600 mg, 1,800 mg or 2,000 mg one or more times a day.
  • Any dosage form for administering the beta-alanine can be used in the methods provided herein.
  • the beta-alanine can be administered as a bolus dosage or as a sustained release or controlled release dosage or a combination of immediate release and controlled release forms.
  • the dosage forms can be formulated to deliver an amount of beta-alanine in a 24 hour period that is between about 0.2 grams and 20 grams. In some methods, a dosage of beta-alanine delivered over a 24 hour period is greater than 1 gram.
  • a dosage of beta-alanine delivered over a 24 hour period is 1.6 grams or more. In some methods, a dosage of beta-alanine delivered over a 24 hour period is 2.4 grams or more. In some methods, a dosage of beta-alanine delivered over a 24 hour period is 3.2 grams or more. In some methods, a dosage of beta-alanine delivered over a 24 hour period is 4.0 grams or more. In some methods, a dosage of beta- alanine delivered over a 24 hour period is 4.8 grams or more. In some methods, a dosage of beta-alanine delivered over a 24 hour period is 5.6 grams or more. In some methods, a dosage of beta-alanine delivered over a 24 hour period is 6.4 grams or more. In some methods, a dosage of beta-alanine delivered over a 24 hour period is 7.2 grams or more. In some methods, a dosage of beta-alanine delivered over a 24 hour period is 8.0 grains or more.
  • the methods can include co-administering a protein and/or one or more essential amino acids.
  • the methods also can include modifying the diet of the subject, such as by increasing protein intake and/or reducing high glycemic index carbohydrate intake.
  • the methods also can include co-administering one or more vitamin and/or mineral supplement.
  • the methods include
  • the methods can include exercise as a step.
  • the exercise can be aerobic exercise or anaerobic exercise or a combination thereof.
  • the methods include administering beta-alanine prior to the exercise.
  • the methods include administering beta-alanine after the exercise.
  • the methods include resistance exercise as a step.
  • the beta-alanine can be administered in a dosage effective to maintain a plasma concentration of beta-alanine above the minimal effective concentration (MEC).
  • the dosage of beta-alanine is effective to maintain a plasma concentration of beta-alanine above the MEC for 10-90% of the time, or between 30-90% of the time, or between 50-90% of the time or between 20-80% of the time.
  • the beta-alanine can be administered at a dosage and over a period of time sufficient to increase muscle carnosine levels at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 100%, or at least 110%, or at least 120% , or at least 130% , or at least 140% , or at least 150% or more from the level before
  • the beta-alanine can be administered at a dosage and over a period of time sufficient to increase muscle carnosine levels to at least 30 mmol/kg dry muscle weight, or at least 40 mmol/kg dry muscle weight, or at least 50 mmol/kg dry muscle weight, or at least 60 mmol/kg dry muscle weight.
  • beta-alanine can be used to prevent, treat, delay, mitigate and/or ameliorate the onset, advancement, severity and/or symptoms of sarcopenia or frailty in a subject.
  • Fig. 2 is a graph showing individual data for absolute change in muscle carnosine content (arbitrary units) from baseline (PRE) to 12-week supplementation period (POST- 12).
  • Fig. 3 is a graph showing time-to-exhaustion in the submaximal exercise test (TLIM; i.e., intensity corresponding to 75% of the difference between ventilatory threshold and V02 peak) at baseline (PRE) and after 12 weeks of beta-alanine supplementation (POST-12).
  • Fig. 4 is a graph showing correlation between percent change in the time-to- exhaustion in the TLIM test (i.e., intensity corresponding to 75% of the difference between ventilatory threshold and V02 peak) and the percent change in the muscle carnosine content.
  • Fig. 6 is a graph showing correlation between percent change in the time-to- exhaustion in the incremental test and the percent change in the muscle carnosine content.
  • active agent refers to a drug or any compound that is a therapeutic agent or a candidate for use as a therapeutic or as lead compound for designing a therapeutic or that is a known pharmaceutical.
  • Such compounds can be small molecules, including small organic molecules, peptides, peptide mimetics, antisense molecules, antibodies, fragments of antibodies, recombinant antibodies.
  • biological activity refers to the in vivo activities of a compound or physiological responses that result upon in vivo administration of a compound, composition or other mixture. Biological activity, thus, encompasses therapeutic effects and
  • the term "physical capacity" refers to a measure of the ability of active muscle systems to deliver, by aerobic metabolism or anaerobic metabolism, energy for mechanical work, and to continue working for as long as possible.
  • the term "assess” and grammatical variations thereof, are intended to include quantitative and qualitative determination in the sense of obtaining an absolute value for the activity of a polypeptide, and also of obtaining an index, ratio, percentage, visual or other value indicative of the level of the activity. Assessment can be direct or indirect.
  • contacting refers to bringing two or more materials into close enough proximity whereby they can interact.
  • contacting can be accomplished in a vessel such as a test tube, a Petri dish, or the like.
  • contacting can be performed in the presence of additional materials.
  • contacting can be performed in the presence of cells.
  • one or more of the materials that are being contacted can be inside a cell. Cells can be alive or can be dead. Cells can or can not be intact.
  • a "combination” refers to any association between two or among more items.
  • the association can be spatial or refer to the use of the two or more items for a common purpose.
  • composition refers to any mixture of two or more products or compounds (e.g., agents, modulators, regulators, etc.). It can be a solution, a suspension, liquid, powder, a paste, aqueous or non-aqueous formulations or any combination thereof.
  • ranges and amounts can be expressed as “about” a particular value or range. “About” is intended to also include the exact amount. Hence “about 5 percent” means “about 5 percent” and also “5 percent.” “About” means within typical experimental error for the application or purpose intended.
  • salts include, but are not limited to, amine salts, such as but not limited to chloroprocaine, choline, ⁇ , ⁇ '- dibenzyl-ethylenediamine, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzyl phenethylamine, 1-para-chloro- benzyl-2-pyrrolidin- -ylmethyl-benzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxy-methyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc; and other metal salts, such as but not limited to sodium
  • Exemplary pharmaceutically acceptable salts include acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methylbromide, methylnitrate, calcium edetate, methylsulfate, camsylate, mucate, carbonate, napsylate, bromide, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, phosphate/ diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutamate, stearate, glycollylarsanilate, sulfate
  • esters include, but are not limited to, alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclo esters of acidic groups, including, but not limited to, carboxylic acids, phosphoric acids, phosphinic acids, sulfonic acids, sulfinic acids and boronic acids.
  • Pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more solvent or water molecules, or 1 to about or 100, or 1 to about or 10, or one to about or 2, 3 or 4, solvent or water molecules.
  • Pharmaceutically acceptable salts include alaninate salts, including, but not limited to, creatine-, -alaninate, tauryl-beta-alaninate alone or complexed with one or more metal ions selected from among zinc, manganese, magnesium, calcium, copper, iron, boron, vanadium, molybdenum, germanium and selenium, nickel, vanadium, silicon, germanium, arsenic, aluminum, cadmium, lithium, cobalt and rubidium and aryl-beta-alaninates, such as benzyl- beta-alaninate.
  • metal ions selected from among zinc, manganese, magnesium, calcium, copper, iron, boron, vanadium, molybdenum, germanium and selenium, nickel, vanadium, silicon, germanium, arsenic, aluminum, cadmium, lithium, cobalt and rubidium and aryl-beta-alaninates, such as benzyl- beta-alaninate.
  • the term "functional food” refers to a food that includes potentially healthful products including any modified food or food ingredient that provides a health benefit beyond the traditional nutrients it contains, and can include a nutraceutical. For example, see (Hasler, Functional Foods: the Western perspective, Nutrition Reviews, 54: S6- S10 (1996)).
  • nutraceutical refers to any substance, agent or combination of agents, that produces a physiological effect in a mammal, such as a medical or health benefit. Nutraceuticals may be derived from natural sources or prepared synthetically.
  • nutraceuticals include but are not limited to bioflavonoids, catechin-based preparations such as proanthocyanidin, acerola concentrate, grape seed extract, pycnogenol, provatene, carotenoids such as ⁇ -carotene, sodium bisulfite, vitamins such as Vitamin E, riboflavin (Vitamin B2), and Vitamin C (L-ascorbic acid), a-tocopherol, all manner of herbal compounds, elderberry extract, lutein, coenzyme Q10, and combinations thereof.
  • bioflavonoids catechin-based preparations such as proanthocyanidin, acerola concentrate, grape seed extract, pycnogenol, provatene, carotenoids such as ⁇ -carotene, sodium bisulfite, vitamins such as Vitamin E, riboflavin (Vitamin B2), and Vitamin C (L-ascorbic acid), a-tocopherol, all manner of herbal compounds, elderberry extract,
  • sample refers to any composition, whether liquid, gas or solid, that includes a molecule or material to be detected or examined.
  • a sample can be water or a buffered solution or be composed of any artificially introduced chemicals, and may or may not contain nucleic acids, amino acids or peptides.
  • the sample can be a biological sample, such as a biological fluid or a biological tissue obtained from any organism or a cell of or from an organism or a viral particle or portions thereof.
  • a drug refers to any compound that is a candidate for use as a therapeutic or as lead compound for designing a therapeutic or that is a known pharmaceutical.
  • Such compounds can be small molecules, including small organic molecules, peptides, peptide mimetics, antisense molecules, antibodies, fragments of antibodies, recombinant antibodies.
  • derivative or “analog” of a molecule refers to a portion derived from or a modified version of the molecule.
  • a “therapeutic agent” or “therapeutic regimen” refers to conventional drugs and drug therapies, which are known to those skilled in the art, and includes compounds that exhibit a therapeutic effect when administered to a subject.
  • C mx refers to the maximum (peak) observed plasma concentration.
  • T max refers to the time to reach the maximum (peak) observed plasma concentration C mx .
  • a "combination” refers to any association between two or among more items.
  • the association can be spatial or refer to the use of the two or more items for a common purpose.
  • composition refers to any mixture of two or more products or compounds (e.g., agents, modulators, regulators, etc.). It can be a solution, a suspension, liquid, powder, a paste, aqueous or non-aqueous formulations or any combination thereof.
  • Fluid refers to any composition that can flow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams and other such compositions.
  • the term “inhibit” refers to the ability of a compound to reduce or impede a described function.
  • Standard refers to something used for comparison.
  • a standard can be a known standard agent or compound that is administered or added to a control sample and used for comparing results when measuring said compound in a test sample.
  • Standard can also refer to an "internal standard,” such as an agent or compound which is added at known amounts to a sample and is useful in determining such things as purification or recovery rates when a sample is processed or subjected to purification or extraction procedures before a marker of interest is measured.
  • the term “treat” or “treatment” refers to an action resulting in a curative treatment or to a lessening or reduction in the severity of a symptom of or a disease or condition or to lessening the frequency of outbreaks of a disease or disorder.
  • the terms include a remitative treatment of a disorder (i.e. treatment that causes the disorder to enter remission).
  • the term “treat” or “treatment” includes administration of an agent where the disease or condition is at least partially improved or ameliorated, and/or there is some alleviation, mitigation or decrease in at least one clinical symptom, and/or there is a delay in the progression of the condition or disease, and/or prevention or delay of the onset of the condition or disease.
  • the terms “treat” and “treatment” refer to both prophylactic and therapeutic treatment regimes.
  • prevention or prophylaxis refers to methods in which the risk of developing disease or condition is reduced.
  • Prophylaxis includes reduction in the risk of developing a disease or condition and/or a prevention of worsening of symptoms or progression of a disease or reduction in the risk of worsening of symptoms or progression of a disease or condition.
  • an "effective amount" of a compound or composition for treating a particular condition or disease is an amount that is sufficient to ameliorate, or in some manner reduce the symptoms associated with the condition or disease. Such amount can be administered as a single dosage or can be administered according to a regimen, whereby it is effective. The amount can cure a disease, but, typically, can be administered in order to ameliorate the symptoms of the condition or disease, or to prevent the onset of the condition or disease. Typically, repeated administration is required to achieve a desired amelioration of symptoms.
  • terapéuticaally effective amount refers to an amount of an agent, such as a beta-alanine, that is at least sufficient to produce a therapeutic effect.
  • An effective amount is the quantity of a therapeutic agent necessary for preventing, curing, ameliorating, arresting or partially arresting a symptom of a disease, condition or disorder.
  • the term “ameliorate” or the term “amelioration of the symptoms” of a particular condition, disease or disorder by administration of a particular compound or pharmaceutical composition that includes the compound refers to any lessening of severity, delay in onset, slowing of progression, or shortening of duration, whether permanent or temporary, lasting or transient, that can be attributed to or associated with administration of the compound or composition containing the compound.
  • the term “prevent” means that a subject does not present the phenotypical symptoms of the disease or condition within the time during which a subject not exposed to the treatment agent, such as beta-alanine, would be expected to develop traits characteristic of the particular disease or condition.
  • the term "mitigate” refers to a decrease in the severity of traits or symptoms of a disease or condition. Mitigation can be quantitated, such as using the methods and parameters described herein or known in the art, and mitigation includes a decrease in the severity of traits or symptoms of a disease or condition of at least 10% compared to subject, equally disposed to develop a particular disease or condition, which has not been exposed to the treatment agent.
  • onset refers to the beginning of detectable traits or symptoms of a disease or condition.
  • the lessening or decrease is statistically significant, e.g., having a P ⁇ 0.05.
  • administering refers, in one embodiment, to bringing a subject in contact with beta-alanine, a salt of beta-alanine, a derivative of beta-alanine or a compound comprising beta-alanine, such as a peptide that includes beta-alanine.
  • “frailty” refers to an adverse, primarily gerontologic, health condition, which can include low functional reserve, accelerated osteoporosis, easy tiring, decreased muscle strength, high susceptibility to disease and decreased libido (e.g., see Bandeen-Roche et ah, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 61 : 262-266 (2006)). Frailty can be characterized by meeting three of the following five attributes: unintentional weight loss, muscle weakness, slow walking speed, exhaustion, and low physical activity.
  • sarcopenia means a loss of skeletal muscle mass, quality, and strength. Sarcopenia may lead to frailty, for example, in the elderly.
  • the term "subject" refers to an animal, such as a mammal, for example a human, that has been or will be the object of treatment, observation or experiment.
  • the methods described herein can be useful in both human therapy and veterinary applications.
  • the subject is a mammal, and in some embodiments, the subject is human. In some embodiments, the subject is a companion animal.
  • animal includes any animal, such as, but not limited to; primates including humans, gorillas and monkeys; rodents, such as mice and rats; fowl, such as chickens; ruminants, such as goats, cows, deer, sheep; ovine, such as pigs and other animals.
  • rodents such as mice and rats
  • fowl such as chickens
  • ruminants such as goats, cows, deer, sheep
  • ovine such as pigs and other animals.
  • Non-human animals exclude humans as the contemplated animal.
  • mammal refers to any animal classified as such, including humans, domestic and farm animals, zoo, sports, or pet animals, such as dogs, horses, cats, sheep, pigs, cows, etc.
  • the term "improvement of muscle function” encompasses the enhancement of the physical performance especially the enhancement of the physical endurance and the fatigue resistance.
  • the phrase "inhibiting the development" of a sign of aging means delaying the onset, slowing the progression, or reducing the manifestation, of a sign of aging.
  • the term “improving performance” refers to any aspect of performance, including cognitive performance or physical performance, such as, but not limited to, the ability to be self-sufficient, to take care of (some but not necessarily all) personal needs, to be ambulatory or otherwise mobile, or interaction with others.
  • muscle strength refers to the ability of a muscle or a group of muscles to produce tension or exert force through the skeletal system.
  • skeletal muscle includes skeletal muscle tissue as well as components thereof, such as skeletal muscle fibers (i.e., fast or slow skeletal muscle fibers), the myofibrils comprising the skeletal muscle fibers, the skeletal sarcomere which comprises the myofibrils, and the various components of the skeletal sarcomere described above.
  • skeletal muscle fibers i.e., fast or slow skeletal muscle fibers
  • myofibrils comprising the skeletal muscle fibers
  • the skeletal sarcomere which comprises the myofibrils
  • Skeletal muscle does not include cardiac muscle or a combination of sarcomeric components that occurs in such combination only in cardiac muscle.
  • power output of a muscle means work/cycle time. Power output may be modulated by changing, for example, activating parameters during cyclical length changes, including timing of activation (phase of activation) and the period of activation (duty cycle).
  • muscle function refers to any one or more physical attributes which can be dependent to any degree on skeletal muscle contraction.
  • muscle functions include, but are not limited to, maximal muscular strength, muscular endurance, running speed and endurance, swimming speed and endurance, throwing power, lifting and pulling power, ability to change position (such as measured by the timed get-up- and-go test), translocation, such as can be evaluated by the timed stand test, and skeletal muscle support and coordination, such as can be measured by a subject's control of balance, such as can be measure by the one-leg balance test (Gillette-Guyonnet et ah, Gerontology 46(4): 189-193 (2000)) or one or more criteria of the Berg balance test.
  • balance refers to the ability of a subject to maintain the center of gravity over a base of support, usually in an upright position.
  • Balance is complex and is a coordinated response of the neuromuscular and musculoskeletal systems. Decline in muscular function leads to a loss of balance control. With good balance, a patient has the ability to sit, stand, or walk safely without falling or requiring an external means of support.
  • muscle catabolism refers to muscle degradation, including during intense exercise and prolonged periods of exertion.
  • muscle anabolism refers to muscle synthesis, generation or regeneration.
  • hand grip strength refers to the maximum isometric strength of the hand and forearm muscles. Handgrip strength is often used as a general test of strength. Handgrip strength has been demonstrated as a predictor of muscle function, including in the oldest old (e.g., see Taekema et ah, Age Ageing 39(3): 331-337 (2010)). Hand grip strength can be measured by use of a dynamometer or any technique known in the art.
  • the term "at-risk subject” refers to a subject who exhibits objective evidence of decline in muscle performance as measured by established methods of physical performance assessment.
  • Appendicular skeletal muscle mass is the mass of the subject divided by the square of the height of the subject (kg/height 2 (m 2 )). Appendicular skeletal muscle mass can be measured by any measurement technique known in the art (e.g., by dual-photon absorptiometry (Heymsfield et ah, Am J Clin Nutr 52: 214-218 (1990)) and DEXA, (Going et ah, Am J Clin Nutr 57: 845-850 (1993), Kellie, JAMA 267: 286-294 (1992), and Roubenoff et ah, Am J Clin Nutr 58: 589-591 (1993)). These techniques permit the body to be segmented into three components: bone, fat, and fat-free soft tissues.
  • appendicular skeletal muscle mass t-score refers to the standard deviation in appendicular skeletal muscle mass in a subject compared to the mean of a young reference group, such as described in Baumgartner et al. (Am J Epidemiol 147: 755- 763 (1998) and Am J Epidemiol 149: 1161 (1998)).
  • a t-score of -1 refers to an appendicular skeletal muscle mass of a subject one standard deviations below the mean of a young reference group.
  • a t-score of -2 refers to an appendicular skeletal muscle mass of a subject two standard deviations below the mean of a young reference group.
  • Baumgartner et al. suggests that sarcopenia is present in a subject having an appendicular skeletal muscle mass less than two standard deviations below the mean of a young reference group.
  • cognitive function refers to any mental component of brain function.
  • cognitive functions include, but are not limited to, attention, concentration, memory and focus.
  • beta. -alanine or " ⁇ -alanine” refers to the naturally occurring beta amino acid that has the IUPAC name ⁇ -amino-propanoic acid (CAS Registry No. 107-95-9).
  • a beta-alanine includes free beta-alanine, a biological source of beta-alanine, a salt of beta-alanine or containing beta-alanine, including alaninate salts, and an ester, ether, amide, azide, oxide, hydrate, solvate or chelate of beta-alanine.
  • a compound that is "a biological source of beta-alanine” is a compound that, when administered to the body by any route (for example parenterally, orally, topically), is converted, e.g., via ionic dissolution to constituent ions or by one or more chemical- or enzyme-catalyzed reaction steps, to beta-alanine, which then appears in blood, plasma or serum and is available for uptake into muscle and other tissues.
  • beta amino acids are amino acids in which the amino group is at the ⁇ -position from the carboxylate group (i.e., two atoms away). Unlike its normal counterpart, L-a-alanine, beta-alanine has no chiral center.
  • creatine refers to the chemical N-methyl-N-guanyl glycine, (CAS Registry No. 57-00-1), also known as (alpha-methyl guanido) acetic acid, N-
  • “creatine” also includes glycocyamine (CAS# 352-97-6), guanidinopropionic acid (CAS# 353-09-3), creatinol (CAS# 6903-79-3; FIG. 2), and cyclocreatine (CAS# 35404-50-3), as well as any salt, ester, ether, amide, azide, oxide, or chelate thereof or of creatine.
  • the term "minimal effective concentration” refers to a concentration of beta-alanine required to increase the mean beta-alanylhistidine level in a tissue by at least 10% as compared to that in the absence of administration of beta-alanine.
  • the term "enteral nutrition product” refers to a supplemental food material that is provided via the gastrointestinal tract by mouth (orally), or through a tube, catheter, or stoma that delivers nutrients distal to the oral cavity. Enteral nutrition, whether orally or by tube feeding, is used as a therapeutic regimen to prevent serious disability or death in a subject with a condition that precludes the full use of regular food.
  • these products are provided to the patient outside of a hospital setting.
  • the products can be provided in a nursing home, out care patient center, or even the home of the patient. Any suitable container can be used to supply the nutrition product.
  • the product is administered so that the patient receives 1500 ml per day, although those skilled in the art will appreciate that variations to the amount of product administered are possible.
  • parenteral nutrition product refers to a food replacement composition that is administered by means other than through the alimentary tract (as by intramuscular or intravenous injection).
  • vitamin D refers to a group of fat-soluble secosteroids, the two major physiologically relevant forms of which are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol).
  • the term also their precursor molecules such as ergosterol (7-dehydro- 22-dehydro-24-methyl-cholesterol) and 7 dehydrocholesterol, 25-hydroxy-vitamin D 3, the 3- hydroxylated dihydrotachysterol 2, the 1 a-hydroxylated alfacalcidol (1 a-hydroxyvitamin D 3) and calcitriol (1 a, 25-dihydroxyvitamin D 3), as well as the numerous natural and synthetic Vitamin D analogs described in Bouillon et ah, Endocrine Reviews 16: 200-257 (1995).
  • vitamin D drug refers to any compound that raises the blood or tissue level of Vitamin D, or has an affinity for the Vitamin D receptor, for example binding to that receptor with a Relative Competitive Index (RCI) of 0.05 or greater.
  • RCI Relative Competitive Index
  • the RCI is indexed to an RCI of 100 for calcitriol.
  • Vitamin D drugs include Vitamin D preparations and analogs, such as Rocaltrol ® (Roche Laboratories), Calcijex ® injectable calcitriol,
  • investigational drugs from Leo Pharmaceutical including EB 1089 (24a,26a,27a-trihomo- 22,24-diene-la, 25-(OH) 2-D 3), KH 1060 (20-epi-22-oxa-24a,26a,27a-trihomo-l a, 25-(OH) 2-D 3), MC 1288 and MC 903 (calcipotriol), Roche Pharmaceutical drugs that include 1,25- (OH) 2-16-ene-D 3, l,25-(OH) 2-16-ene-23-yne D 3, and 25-(OH)2-16-ene-23-yne-D 3, Chugai Pharmaceuticals 22-oxacalcitriol (22 oxa-la,25-(OH) 2-D 3; la-(OH)D 5 from the University of Illinois; and drugs from the Institute of Medical Chemistry-Schering AG that include ZK 161422 and ZK 157202.
  • unit dosage forms refers to physically discrete units suitable for human and animal subjects. Each unit dosage includes a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with, when required, a pharmaceutical carrier, vehicle or diluent. Examples of unit dosage forms include tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, ampoules and syringes, and oral solutions or suspensions, and oil- water emulsions. Unit dosage forms can be individually packaged as is known in the art, such as in blister packs. Unit dosage forms can be administered in fractions or multiples thereof.
  • yielderly refers to an individual who has reached the age of 65 years or older.
  • geriatric refers generally to an adult individual who has reached old age.
  • the term “improving gait” or “improvement in gait” refers to one or more of an increase in stride length, a decrease or reduction in stride frequency and/or a decrease or reduction in stance width variability and/or a decrease in stride length variability in a subject following administration of a beta-alanine to the subject, relative to the stride length, stride frequency, stance width variability, and/or stride length variability before treatment with beta-alanine.
  • the term "stride length" refers to the distance traveled during one cycle of gait (e.g., the distance traveled between the point at which a foot, paw, knee, hand, etc. of a moving (e.g., ambulating) subject departs contact with a primary supporting surface (e.g., the ground or other walking surface) and the point at which the same foot, paw, knee, hand, etc. of the subject next contacts the supporting surface.
  • a primary supporting surface e.g., the ground or other walking surface
  • standardized average stride length refers to the average measured value for stride length observed for a population that has not been selected for, or is not anticipated to have been selected for, a disease, disorder or any other attribute that alters, or would be anticipated to alter, the measured average stride length of the population.
  • the term “stride frequency” refers the number of strides taken in a given amount of time or over a given distance.
  • the term “ergogenic” refers to the ability to increase capacity for bodily and/or mental labor, especially by reducing or eliminating signs and symptoms of fatigue.
  • ready-to-drink meal replacement beverage refers to any liquid beverage providing nutrition, including the vitamins and minerals known to be essential for human health, as well as protein, carbohydrate and/or fat, for example, including but not limited to Unilever's Slimfast ® , Abbott's Ensure ® , or Mead Johnson's Boost ® meal replacement beverages.
  • anaerobic means without oxygen
  • anaerobic exercise refers to exercise that does not increase the body's requirement for oxygen.
  • anaerobic exercise can be a short-burst, higher-intensity exercise.
  • Proteins and carbohydrates may be utilized to build muscle mass and/or strength.
  • Fat burning may be an indirect effect of anaerobic exercise.
  • Anaerobic exercise may include, for example and not by way of limitation, push-ups, pull-ups, sit-ups, sprinting, stomach crunches, weight lifting and strength training.
  • oxygen means with oxygen
  • aerobic exercise refers to exercise that increases the body's requirement for oxygen.
  • aerobic exercise involves an increased respiratory rate and cardiac rate over an extended period of time.
  • the body usually requires the utilization of stored fat deposits as fuel for muscle contraction. Therefore, aerobic exercise can be considered to have a direct fat burning effect.
  • Aerobic exercise may include, for example and not by way of limitation, basketball, bicycling, cross-country skiing, ice hockey, ice skating, jogging, martial arts, rollerblading, rowing, soccer, swimming, tennis and walking (e.g., at a fast pace).
  • resistance exercise refers to exercise that is performed by a subject against resistance, e.g., as from a weight.
  • V0 2max or “V0 2pea k” refers to the maximal amount of oxygen that can be transported and utilized for energy production during exercise, including during incremental or exhaustive exercise. can be used to gauge the physical fitness of an individual.
  • the term “functional reserve” refers to the remaining capacity of an organ or body part to fulfill its physiological activity. Functional reserve can be impaired or decline do to disease and/or ageing.
  • skeletal muscle tissue function refers to strength, endurance, or motor control. Improving one of these three variables, alone or in combination, results in improved muscle function. Skeletal muscle tissue function includes the ability of muscle to perform a physiologic function, such as contraction, as measured by the amount of force generated during either twitch or tetanus.
  • Methods for assessing muscle function include, but are not limited to, measurements of muscle mass, grip strength, serum CK level, activities of daily living, motion or strength tests, tissue histology (e.g., collagen III staining), or tissue imaging.
  • the "Berg balance test” refers to an observational performance-based assessment tool that is used to evaluate an individual's balance function during functional activities.
  • the Berg Balance test is a well-known example of an observational test with documented ability to detect fall risk.
  • the Berg test requires a clinically trained individual to observe and numerically rate an individual's ability to perform a series of standardized balance and movement tasks. This test has the advantage of requiring no specialized equipment.
  • the subject is scored on a combination of different tasks, which include changing position from sitting to standing, changing position from standing to sitting, sitting without support, standing without support, standing with eyes closed, standing with feet together, standing on one leg, tandem standing, turning trunk with feet fixed, turning 360 degrees, retrieving objects from the floor, reaching forward while standing and stepping on a stool.
  • Each of the difference tasks is assigned a numerical value from 0 to 4.
  • Subjects that score 20 or less have poor balance, and may be confined to a wheelchair.
  • Subjects with a score between 21 and 40 generally display some problem maintaining balance and may require assistance while walking.
  • Subjects scoring 41 or above generally can control their balance and can walk independently. On average, subjects with scores less than 40 are much more likely to fall than subjects with scores higher than 40.
  • controlled release coat refers to a functional coat that can, e.g., include at least one pH independent polymer, pH dependent (such as for example enteric or reverse enteric types) polymer, soluble polymer, insoluble polymer, lipids, lipidic materials or combinations thereof which when applied onto a dosage form can slow (for example when applied to a normal release matrix dosage form), further slow (for example when applied to a controlled release matrix dosage form) or modify the rate of release of the beta-alanine when applied to an uncoated dosage form.
  • pH dependent such as for example enteric or reverse enteric types
  • control releasing coat can be designed such that when the control releasing coat is applied to a dosage form, the dosage form in conjunction with the control releasing coat can exhibit the release of the beta-alanine, such as for example, as a "modified-release,” “controlled-release,” “sustained- release,” “extended-release,” “delayed-release,” “prolonged-release” or combinations thereof.
  • the "control releasing coat” can optionally include additional materials that can alter the functionality of the control releasing coat.
  • co-administer refers to administering more than one pharmaceutical agent to a subject.
  • co-administered pharmaceutical agents are administered together in a single dosage unit.
  • coadministered pharmaceutical agents are administered separately.
  • co- administered pharmaceutical agents are administered at the same time.
  • co-administered pharmaceutical agents are administered at different times.
  • Beta-alanine or 3 -amino-propanoic acid, is formed in vivo by the degradation of dihydrouracil and carnosine, and is readily obtained from meat in a carnivorous or omnivorous diet. Beta-alanine is a component of a number of naturally occurring
  • beta-alanylhistidine peptides including carnosine and anserine as well as being a component of pantothenic acid (vitamin B5).
  • Beta-alanine is the rate-limiting precursor of the synthesis of carnosine. Supplementation with beta-alanine has been shown to increase the
  • Beta-alanine and L-histidine and their methylated analogues form dipeptides within the human or animal body.
  • the di-peptides produced from beta-alanine and histidine include carnosine (beta-alanyl-L-histidine), anserine (beta-alanyl-L-l-methyl-histidine), or balenine (beta-alanyl-L-3-methylhistidine) (referred to collectively herein as beta-alanylhistidine peptides).
  • Beta-alanylhistidine peptides are involved in the regulation of intra-cellular pH homeostasis during muscle contraction and, therefore, are involved in the regulation of muscle fatigue.
  • Beta-alanylhistidine peptides provide an effective way of accumulating pH- sensitive histidine residues in a cell.
  • variations in the muscle beta-alanylhistidine peptide concentrations affect the anaerobic work capacity of muscles, and increasing the amount of beta-alanylhistidine peptides within a muscle favorably affects performance and the amount of work that can be performed by the muscle.
  • Beta-alanine and L-histidine can be produced by the body or can be obtained through the diet that includes a meat protein source. Within the body, beta-alanine is transported to tissues such as muscle. Since in a typical fed state, the concentration of beta-alanine in muscle is low in comparison with the concentration of L-histidine, the concentration of beta- alanine is likely limiting to the synthesis of beta-alanylhistidine peptides.
  • beta-alanylhistidine peptides in a human or animal body can be increased by increasing the blood or blood plasma concentrations of beta-alanine, increasing the blood or blood plasma concentrations of beta-alanine and creatine, or increasing the blood or blood plasma concentrations of beta-alanine, L-histidine, and creatine.
  • Beta-alanine supplementation can increase athletic performance by reducing fatigue or reducing the time to the onset of fatigue associated with lactic acid and/or hydrogen ion accumulation during intense exercise or prolonged athletic activity.
  • beta-alanine supplementation strategies of daily doses of between 200 mg to 6,400 mg, generally following a regime that includes administration of multiple doses of 200 mg, 400 mg or 800 mg tablets multiple times per day, administered at regular intervals for up to eight hours, over periods ranging from 4 to 10 weeks (e.g., see Culbertson et al., Nutrients 2: 75-98 (2010)). After a 10 week supplementation period, the reported increase in intramuscular carnosine content was between 20-80%.
  • beta-alanine can prevent the progression of and even partially reverse symptoms of sarcopenia and/or frailty.
  • methods of maintaining or increasing muscle mass and/or strength and/or muscle functionality to treat sarcopenia or frailty in a subject comprising administering to the subject a therapeutically effective amount of beta-alanine.
  • Muscle functionality is an important attribute in the ageing subject. Muscle functionality can be a deciding criteria between deciding whether a subject can be considered sufficiently functional to live alone or if the subject requires assistance with everyday tasks. Functional activities such as standing from a seated position, reaching for and retrieving an object, bending, transferring, walking and standing require muscle functionality. These activities also can be influenced by a subject's ability to control their balance. Subjects that exhibit a declines in muscle function also exhibit a loss of balance. Loss of balance and muscle function can lead to increased risk of falls and increased occurrence of falls.
  • the Berg Balance Test is an observational performance-based assessment used to evaluate standing balance during a number of functional activities.
  • the Berg Balance Test includes 14 subtests, which include changing position from sitting to standing, standing without support, sitting without support, changing position from standing to sitting, pivot transfers to go from one chair to another, standing with eyes closed, standing with feet together, reaching forward with an outstretched arm, retrieving an object from the floor, turning to look behind over left and right shoulders while standing, turning 360 degrees (completely turn around in a full circle), placing alternate foot on step or stool while standing unsupported, standing unsupported with one foot directly in front of the other and standing on one leg.
  • the subject is scored on his/her performance during different tasks.
  • the Berg Balance Test has been used in the art to predict falls in elderly persons (e.g., see Berg, Physiotherapy Canada 41(6): 240-245 (1989); Bogle Thorbahn et al, Physical Therapy 76(6): 576-585 (1996) and Perell et al, The Journals of Gerontology: Series A 56(12): M761- M766 (2001)).
  • the test often is administered to subjects who exhibit a decline in function, report a loss of balance, or experience falls.
  • the Berg Balance Test was developed in the early 1990s to measure balance in the elderly. Over the years it has been shown to be a reliable test for evaluating balance.
  • the measured elements of the test are representative of daily activities that require balance, such as sitting, standing, leaning over to pick up an object and stepping.
  • Some tasks are rated according to the quality of the performance of the task, while others are evaluated by the time required to complete the task.
  • the scores assigned for the performance of the task are between 0 (cannot perform the task) to 4 (normal performance of the task). Score below 14 indicated greatly impaired balance while a perfect score of 56 indicates excellent balance (see, e.g., Wood-Dauphinee et ah, Canadian J Rehabilitation 10: 35-50 (1997); Berg et ah, Scand J Rehab Med 27: 27-36 (1995); Berg et ah, Arch Phys Med Rehabilitation 73 : 1073-1083 (1992); and Berg et ah, Physiotherapy Canada 41 : 304-311 (1989)). These values can be used for assessing independent living ability.
  • subjects with a score of less than 20 generally have little to no balance and require a wheelchair or other mechanical means to get from one place to another. Such subjects generally would be unable to live independently without some supervision and/or monitoring.
  • Subjects with a score between 21 and 40 exhibit some loss of balance and muscle function, and generally require some assistance to perform every day activities, such as walking, retrieving an item, such as from a shelf or from the floor, and walking.
  • Subjects with a score or 41 and above exhibit good balance and can perform routine daily tasks with little or no assistance and can live independently. More often than not, subjects with a score of 40 or less tend to experience falls with much higher frequency than subjects with scores higher than 40.
  • administering beta-alanine can improve the score of a subject on the Berg balance test.
  • the score can be improved by 2 or more.
  • the score can be improved so that it is in the range of 21 to 40.
  • the score can improved to be in a range between 25 and 45.
  • the score can improved to be in a range between 30 and 50.
  • the score can improved to be greater than 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or greater.
  • administration of beta-alanine to an elderly subject can result in improvement of one or more measures of muscle functionality, including balance, timed up and go test results, functional reach test results, step tests results, rapid step test results, four square step test results, multi-directional reach test results, lateral reach test results, increased ability to stand with the feet together in a side-by-side configuration and/or in a semi-tandem and/or tandem position, and timed stand tests.
  • measures of muscle functionality including balance, timed up and go test results, functional reach test results, step tests results, rapid step test results, four square step test results, multi-directional reach test results, lateral reach test results, increased ability to stand with the feet together in a side-by-side configuration and/or in a semi-tandem and/or tandem position, and timed stand tests.
  • Other assessment tests of muscle function in the elderly can be used. These include functional reach tests, lateral reach tests, step tests, four square step test, elderly mobility scale tests, sensory oriented mobility assessment instrument (SOMAI) testing, Fullerton advanced balance scale, Tinetti performance orientated mobility assessment, change of direction while stepping, and hierarchical assessment of balance and mobility (e.g., see Lord et ah, J Am Geriatrics Soc 49(5): 508-515 (2001); Farrell et ah, Topics Geriatric Rehabilitation 20(1): 14-20 (2004); Bennie et al, J Physical Therapy Science 15(2): 93-97 (2003); Dite et al, Archives of Physical Medicine and Rehabilitation 83 : 1566-1571 (2002); Steffen et al., Physical Therapy 82(2): 128-137 (2002); and Langley et al., The Internet Journal of Allied Health Sciences and Practice, Volume 5, Number 4 (2007)).
  • SOMAI sensory oriented mobility assessment instrument
  • Beta-alanine can be used as a frailty suppressive agent and as a muscle enhancing agent or muscle increasing agent (providing effects of reducing muscle fatigue in the elderly, preventing elderly hospitalized subjects or patients from being bedridden, shortening rehabilitation period, and improving muscle function) and as an agent for the prophylaxis or treatment of muscle decrease due to disease or misuse, alone or as an adjunct to exercise, and in particular resistance exercise.
  • the methods include administering beta-alanine before, concurrent with, or after other optional components such as other active ingredients.
  • the method includes as a step co-administering a beta-alanine with one or more of the following ingredients: creatine (including its salts (e.g., creatine monohydrate), esters (e.g., creatine ethyl ester), chelates, amides, ethers and derivatives thereof), histidine, vitamin D, Vitamin C, Vitamin B l, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, and/or Vitamin K, a mineral, such as chromium, iron, magnesium, sodium, potassium, vanadium, an amino acid, such as L-arginine, L-ornithine, L-glutamine, L-tyrosine, L-taurine, L-leucine, L-isoleucine, L-theanine and/or L-valine and derivatives thereof, one or more peptides, such
  • the beta-alanine can be provided as free beta- alanine, or a salt, ester, ether, amide, azide, oxide, or chelate of beta-alanine, including creatine-beta-alaninate salts, or a biological source of beta-alanine.
  • a compound that is a biological source of beta-alanine is a compound that, when administered to the body by any route (for example parenterally, orally, topically), is converted, e.g., via ionic dissolution to constituent ions or by one or more chemical- or enzyme-catalyzed reaction steps, to beta- alanine, which then appears in blood, plasma or serum and is available for uptake into muscle and other tissues.
  • the free beta-alanine or a biological source thereof may be derivatized as the corresponding salts, esters, enol ethers or esters, acids, bases, solvates, hydrates or pro-drugs prior to administration, as is known in the art.
  • the effective amount of beta-alanine to be administered can vary according to factors such as age, sex, and weight of the individual.
  • the dosage schedule and regime can be adjusted to provide the optimum response in the individual.
  • Several divided doses can be administered daily, or the dose may be proportionally reduced as indicated by the exigencies of an individual's situation.
  • the beta-alanine or a composition containing beta-alanine can be administered as a dietary supplement, and can be administered in a single serving or in multiple servings spaced throughout the day.
  • servings need not be limited to daily administration, and may be on an every second or third day or other convenient effective basis.
  • the administration on a given day can be in a single serving or in multiple servings spaced throughout the day depending on the exigencies of the situation.
  • the composition can be formulated for bolus administration or for sustained release administration.
  • beta-alanine can result in symptoms of paraesthesia. These symptoms include tingling sensations in various parts of the body, particularly in the head and neck region. Once the body is accustomed to the beta-alanine, the tingling symptoms usually stop or become much less pronounced or perceivable. It generally is recommended that a dosage of 1 gram per 2 hour period not be exceeded in order to minimize symptoms of paraesthesia (Derave et ah, Sports Med. 40(3): 247-263 (2010)). Controlled or sustained release formulations have been shown to minimize or eliminate symptoms of paresthesia (e.g., see U.S. Pat. App. Pub. No. US20090220575). Thus, in some embodiments, the methods include administration of beta-alanine in a controlled release formulation.
  • the beta-alanine is encapsulated or embedded in a matrix that allows for controlled or sustained release of the beta-alanine from the matrix.
  • a sustained-release system is a semipermeable matrix of solid hydrophobic and/or hydophilic polymers.
  • sustained release systems can, depending on their chemical nature, release compounds over a period of hours, days, weeks or months.
  • Controlled release delivery systems are known to those of ordinary skill in the art. They can include polymer based systems, which can include such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, lipids, polyesterimide, polyorthoesters,
  • the formulations also can include en encapsulating coating. Microcapsules of the foregoing polymers containing drugs are described in, for example; U.S. Pat. No. 5,075, 109. Delivery systems also can include lipids, triglycerides, waxes, cholesterol, cholesterol esters and fatty acids or neutral fats such as mono- di- and tri-glycerides, hydrogel release systems, and peptide based systems. Specific examples include, but are not limited to: (a) erosional systems in which the platelet reducing agent is contained in a form within a matrix such as those described in U.S. Pat. Nos.
  • the oral ingestion of encapsulated beta-alanine or of a composition including a matrix containing beta-alanine yields a peak concentration (C max ) less than equimolar amounts of orally ingested bolus beta-alanine but greater than that of orally ingested peptides containing beta-alanine, such as anserine or carnosine.
  • the controlled release composition is formulated such that the time to peak concentration (T mx ) of the controlled release beta-alanine is longer than that of equimolar amounts of orally ingested bolus beta- alanine but less than that of orally ingested peptides containing beta-alanine, such as anserine or carnosine.
  • the methods provided herein increase the skeletal muscle level of carnosine in an animal. In some embodiments the methods provided herein increase muscle buffering capacity and thereby allows longer periods of exercise before onset of muscle fatigue in an individual.
  • Sarcopenia is recognized to be a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life and death (see Cruz-Jentoft et ah, Age and Ageing 39(4): 412-423 (2010)). Protocols for assessing the symptoms of sarcopenia in a subject are known in the art (e.g., see Working Group on Functional Outcome Measures for Clinical Trials, J Gereontology A Biol Sci Med Sci 64A(4): 487-491 (2009); and Rolland et al, Journal of Nutrition, Health & Aging 12(7): 433-450 (2008)).
  • Sarcopenia can be defined using a number of criteria, including the amount of muscle and its function.
  • the quantifiable variables are muscle mass, strength and physical performance. The challenge has been how to accurately quantify each of these attributes.
  • Muscle mass can be measured using any method known in the art (e.g., see U.S. Pat. No. 5,628,328; Heymsfield et al, Am J Clin Nutrition, 37: 478-494 (1983); Visser et al, J Appl Physiol 87: 1513-1520 (1999); Ohkawa ei a/., Am J Clin Nutrition, 71(2): 485-490 (2000)). Muscle mass can be quantified by using, e.g., an imagining technique, such as computed tomography (CT scan), dual energy X-ray absorptiometry (DXA) and magnetic resonance imaging (MRI).
  • CT scan computed tomography
  • DXA dual energy X-ray absorptiometry
  • MRI magnetic resonance imaging
  • an amount of beta-alanine is provided to increase the carnosine content in an elderly subject.
  • Muscle carnosine content can be assessed using any method known in the art.
  • muscle carnosine content can be assessed in vivo by X H-MRS (magnetic resonance spectroscopy) using a whole body 3.0T MRI scanner (Achieva Intera, Philips, Best, The Netherlands) and a 14 cm diameter ⁇ -surface coil to detect labelled carnosine (such as from synthesis using labeled beta-alanine).
  • the surface coil can be placed centered under the calf muscle of one leg.
  • the scanner body coil can be used to obtain conventional anatomical Tl-weighted magnetic resonance images in the three orthogonal planes.
  • Spectrum raw data can be analyzed using any method or software known in the art, such as by Java Magnetic Resonance User Interface software (e.g., see Naressi et al., Computers in Biology and Medicine 31(4): 269-286 (2001); and Liao, Computer Methods and Programs in Biomedicine 67(2): 155-162 (2002)).
  • the analysis can include apodization to 5Hz, Fourier transform, phase correction or any combination thereof.
  • the carnosine signal in the muscle can be quantified relative to an external reference.
  • sarcopenia is defined as being less than two standard deviations below the mean of a young reference group (i.e., the t-score).
  • a t-score is determined by measuring the axial skeletal muscle mass of a subject, typically by DXA (i.e., dual energy x-ray absorptiometry) or a similar and reproducible measure. The measurement of axial skeletal muscle mass can be used to follow the progress of the subject to determine if treatment is slowing, preventing, or reversing muscle mass decline. Examples of t-scores include 3, 2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3,
  • muscle strength Another parameter that can be measured for the diagnosis of and confirmation of efficacy of interventions for the treatment of sarcopenia or frailty is muscle strength.
  • the generally accepted measurement criterion for the maximum tension which can be exerted by a muscle is the maximum amount of force a muscle can exert on a body part. In physiology, this is referred to as the maximum strength of the muscle and might be expressed, for example, in kilograms per square centimeter of muscular section. Muscle strength can be expressed in kilograms, Newtons, pounds or inch-pounds and Newton-meters. Techniques to measure muscle strength are known in the art (e.g., see U.S. Pat. Nos. 3, 133,355; 6,063,044; and 6,706,003 and U.S. Pat. Appl. Pubs. US20050245848 and US20010029342). These techniques include isometric muscle strength testing methods, isometric manual muscle testing, and comparison of force and displacement measurements.
  • Muscle strength measurements can include muscle strength of lower limbs, of upper limbs, or their combination. In some instances, the measurement of upper limbs is preferable to the measurement of lower limbs, while in other circumstances the reverse is true. For example, in assessing load bearing strength, measurement of the upper limbs alone may be a good measurement of muscle strength. In the case of the ability to relocate massive objects, the measurement of the combination of upper and lower limb strength may be indicated. For evaluating gait, walking and stair climbing, measurement of lower limb strength may be indicated.
  • One muscle strength measurement used in the art is isometric hand grip strength (e.g., see U.S. Pat. Nos. 4,674,330; 5, 170,663; and 6,678,549). It has been shown that hand grip strength correlates well with other muscle strength testing techniques, including knee extension torque, lower extremity muscle power and with calculations of muscle strength based on cross-sectional area of calf muscle (e.g., see Laurentani et al., J Appl Physiol 95: 1851-1860 (2003)). Handgrip strength has been demonstrated as a predictor of muscle function, including in the oldest old (e.g., see Taekema et al., Age Ageing 39(3): 331-337 (2010)). Grip strength can be measured by any method known in the art, including by use of a handheld dynamometer in comparison to a reference population (Febrer et al., J Rehabil Med. 42(3): 228-231 (2010)).
  • lower extremity muscle strength can be measured using a leg extension movement, such as by using the method described by Bassey et al. (Eur J Appl Physiol 60: 385-390 (1990)). These measurements can be performed isokinetically or isometrically. The isokinetic strength tests, particularly of the knee and ankle, have been demonstrated to be reproducible in older adults (e.g., see
  • the Working Group on Functional Outcome Measures for Clinical Trials has described a number of physical performance test procedures for testing the elderly for symptoms or sarcopenia and/or frailty (J Gerontol A Biol Sci Med Sci 63 : 160-164 (2008)). These include the stair climb power test, 6-min walk test and usual gait speed. Other physical performance tests for assessing lower extremity function are described in the art (e.g., see Guralnik et ah, J Gerontol 49:M85-M94 (1994)). After years of testing, it has been suggested that gait speed can be used as a predictor of adverse outcomes (Abellan van Kan et ah, J Nutr Health Aging 13 : 881-889 (2009)).
  • the timed get-up- and-go test is a gross measure of balance and lower extremity function (e.g., see Mathias et ah, Arch Phys Med Rehabil 67: 387 (1986); Morris et ah, Phys Ther 81 : 810 (2001); Okumiya J Am Geriatr Soc 46: 928 (1998); and Shumway-Cook Phy Ther 80: 896 (2000)).
  • the time needed by a subject to rise from a standard arm chair, walk to a line on the floor three meters away, turn, return, and sit down again is measured.
  • stair climb muscle power test Another testing procedure for measuring muscle functionality is the stair climb muscle power test (e.g., see U.S. Pat. No. 6,972,124). It is known in the art that the stair climb test is a clinically relevant measure of leg power impairments in at-risk older adults and can be used to assess mobility performance (e.g., see Roig et ah, Am. J. Respir. Crit. Care Med. 181 : A3583 (2010); Bean et ah, Arch Phys Med Rehabil 88: 604-609 (2007) and Herman et ah, J Gerontol A Biol Sci Med Sci. 60(4): 476-480 (2005)).
  • the timed stand test is a measure of leg muscle strength and assesses the time needed for a subject to rise from a chain a given number of times as quickly as possible (e.g., see Csuka et ah, Am J Med 78: 77-81 (1985).
  • the test is a simple method for measuring lower extremity muscle strength. In some protocols, the test measures the time needed for a subject to stand 10 times from a standard chair.
  • Other testing procedures can be used to assess muscle function in an elderly subject. These include up and down tests, functional reach tests, lateral reach tests, step tests, four square step test, elderly mobility scale tests, sensory oriented mobility assessment instrument (SOMAI) testing, Fullerton advanced balance scale, Tinetti performance orientated mobility assessment, change of direction while stepping, and hierarchical assessment of balance and mobility (e.g., see Lord et ah, J Am Geriatrics Soc 49(5): 508-515 (2001); Farrell et ah, Topics Geriatric Rehabilitation 20(1): 14-20 (2004); Bennie et ah, J Physical Therapy Science 15(2): 93-97 (2003); Dite et ah, Archives of Physical Medicine and Rehabilitation 83: 1566-1571 (2002); and Langley et ah, The Internet Journal of Allied Health Sciences and Practice, Volume 5, Number 4 (2007)).
  • SOMAI sensory oriented mobility assessment instrument
  • the beta-alanine improves muscle functionality and also can improve exercise tolerance.
  • Other parameters that can be measured to assess efficacy of an intervention for the treatment or prevention of sarcopenia and/or frailty includes results from physical capacity tests. These tests include specific objective physiological measurements such as maximum oxygen uptake (V0 2ma x) (see MacVicar et ah, Nurs Res 3 : 348-351. (1989)) and ventilatory anaerobic threshold (VAT) (see Kreider et ah, Med Sci Sports Exerc. 22(2): 250-256 (1990). Anaerobic exercise testing also can be performed to assess physical capacity (e.g., see U.S. Pat. Nos. 6, 176,241).
  • An exemplary test is a cycle ergometer test to the limit of tolerance (e.g., see Puente-Maestu et al., Respiration 70: 367-370 (2003).
  • a subject performs an incremental test on a motorized treadmill to determine the ventilatory anaerobic threshold (VAT) and A "Wingate test,” which is a cycle ergometer test used to measure muscle work over a relatively short period (e.g., 30 seconds) also can be used.
  • VAT ventilatory anaerobic threshold
  • a "Wingate test” is a cycle ergometer test used to measure muscle work over a relatively short period (e.g., 30 seconds) also can be used.
  • assessment of anaerobic exercise capacity is evaluated by subjecting a subject to one repetition square-wave transition from rest to exercise intensity corresponding to 75% (Delta), i.e., 75% of the difference between VAT and to the limit of tolerance (TLIM), which is similar to the cycle ergometer test described by Puente- also can be determined by having subjects cycle on a stationary cycle ergometer using four 5- min steady-state stages [100, 150, 200, and 250 work rate (W)] followed by a progressive increase in work of 10 W/min until voluntary exhaustion.
  • a work rate of 75% can be calculated for each subject from the linear function of oxygen uptake at the four steady-state work rates, and maximal oxygen uptake against the work rate of the four steady state work rates and maximal power output.
  • Secondary sarcopenia refers to age-related sarcopenia when no other cause is evident but ageing itself. When one or more other causes are evident, the loss of muscle mass and strength or function is considered secondary sarcopenia.
  • secondary sarcopenia include "lack of activity" causes, such as bed rest, confinement to a wheelchair or sedentary lifestyle, sarcopenia related to improper nutrition, such as inadequate dietary intake of protein, nutrient malabsorption, or gastrointestinal disorders or anorexia, and sarcopenia caused by disease, such as
  • Treating sarcopenia includes slowing its progression, stopping its progression, and partially reversing its progression.
  • An example of slowing the progression of sarcopenia would be to change the length of time a subject would go from a t-score of— 1.5 to a score of — 2 (e.g., if such a progression would normally take 5 years, then treating as used herein could slow this change to 10 years).
  • Examples of partial reversal include reducing a t-score 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 or more units (e.g., moving from a t-score of— 2 to a t-score of-1.9,—1.8,—1.7,—1.6,—1.5,—1.4,—1.3,—1.2,—1.1, etc.).
  • the method includes identifying a subject having a t- score selected from among (a) ⁇ -3, (b) ⁇ -2.5, (c) ⁇ -2, (d) ⁇ -1.5, (e) ⁇ -1.0, and (f) ⁇ -0.5; and administering beta- alanine to slow, stop or reverse the progression of sarcopenia.
  • Treating sarcopenia also includes delaying the onset of sarcopenia. For example, if a typical male age 60 would begin to see signs of sarcopenia by age 65, treatment could delay the onset 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years. Thus, treating sarcopenia would include treating subjects who have not yet been diagnosed with sarcopenia, but who would be vulnerable or expected to be vulnerable to developing sarcopenia in the future.
  • Subjects who are vulnerable or expected to be vulnerable in the future also include (a) subjects using glucocorticoid steroids, (b) subjects with chronic infections, (c) subjects with chronic inflammatory conditions (e.g., inflammatory bowel disease), (d) subjects with cancer and (e) patents with a family history of sarcopenia.
  • a further decline in t- score is prevented via treatment with beta-alanine for at least a year.
  • an increase in the t-score of subject is obtained via treatment with beta-alanine for at least a year.
  • Another type of subject that would benefit from the methods provided herein is a subject who has suffered some loss of muscle mass, but who does not suffer from a condition that interferes with acts of daily living and/or prevents the subject from living an independent life (e.g., a subject who might soon need assisted living).
  • the age or age range of the subject can vary depending on their susceptibility to sarcopenia.
  • Examples of ages and age ranges include (a) 40-45, (b) 45-50, (c) 50-55, (d) 55- 60, (e) 60-65, (f) 65-70, (g) 70-75, (h) 75-80, (i) 80-85, (j) 85-90, or older.
  • Frailty generally is associated with old age. Frailty is a geriatric syndrome resulting from age-related cumulative declines across multiple physiologic systems, with impaired homeostatic reserve and a reduced capacity of the individual to withstand stress, thus increasing vulnerability to adverse health outcomes including falls, hospitalization, institutionalization and death (see Cruz-Jentoft et ah, Age and Ageing 39(4): 412-423 (2010)). Protocols for assessing the symptoms of frailty in a subject are known in the art (e.g., see Working Group on Functional Outcome Measures for Clinical Trials, J Gereontology A Biol Sci Med Sci 64A(4): 487-491 (2009)). Because of the ageing world population, age- related frailty has emerged as an important public health problem.
  • Frailty can result in impaired mobility and decreased quality of life, and is associated with increased risk of falls (Roubenof, J Nutr. 129: 256S-259S (1999)).
  • Evidence for a phenotype of frailty has been proposed, based on readily identifiable physical aspects, which includes the manifestation of three or more of the following characteristics: unintended weight loss, exhaustion, weakness, slow gait speed and low physical activity (Fried et ah, J Gerontol A Biol Sci Med Sci 56:M146-56 (2001)).
  • Frailty and sarcopenia include similar underlying etiologies and thus overlap to some extent, but frailty also includes other attributes, such as changes in cognitive status (Bauer et ah, Exp Gerontol 43 :674-678 (2008)).
  • Skeletal muscle fibers are generally classified as type I (oxidative/slow) or type II (glycolytic/fast) fibers. They display marked differences in respect to concentration, metabolism, and susceptibility to fatigue.
  • Type I fibers are mitochondria-rich and mainly use oxidative metabolism for energy production, which provides a stable and long-lasting supply of ATP, and thus are fatigue-resistant.
  • Type II fibers comprise three sub-types: Ila, IIx, and lib.
  • Type lb fibers have the lowest levels of mitochondrial content and oxidative enzymes, rely on glycolytic metabolism as major energy source, and are susceptible to fatigue, while the oxidative and contraction functions of type Ila and IIx lie between type I and lib.
  • skeletal muscle can modulate between different fiber types, such as in response to exercise training (e.g., see Wang et ah, PLoS Biology 2(10): e294 (2004)).
  • Muscle function can become compromised by many mechanisms. Examples include the frailty associated with old age and sarcopenia. Determination of the muscle fiber composition in athletes revealed that elite endurance athletes have relatively more type I fibers than type II fibers in the trained musculature. Marathoners also tend to have more type I fibers. It was suggested that type I fiber might be a factor governing physical endurance capacity. Ageing and physical inactivity are conditions associated with a decrease in type I fibers. It appears that the muscle oxidative capacity is a crucial factor for determining endurance and fatigue resistance. There seem to be an adaptive metabolic response of skeletal muscle to endurance exercise by controlling the number of oxidative muscle fibers (type I fibers).
  • Muscle wasting is characterized by a progressive loss of muscle mass, weakening and degeneration of muscles especially the skeletal or voluntary muscles and the cardiac muscles.
  • the processes by which atrophy and hypertrophy occur are conserved across mammalian species. Multiple studies have demonstrated that the same basic molecular, cellular, and physiological processes occur during atrophy in both rodents and humans.
  • rodent models of skeletal muscle atrophy have been successfully utilized to understand and predict human atrophy responses.
  • an increasing proportion of skeletal muscle is replaced by fibrous tissue. Therefore, normal aging in humans is associated with progressive decrease in skeletal muscle mass and strength and function, which contributes to frailty and falls.
  • Conditions resulting in muscle wasting can arise from disuse conditions such as long term immobilization due to illness or disability such as confinement in a wheelchair, prolonged bed rest, bone fracture or trauma. It is estimated that bed-rest after surgery causes loss of skeletal muscle mass of approximately 10% per week. Untreated muscle wasting disorders can have serious health consequences. The changes that occur during muscle wasting can lead to a weakened physical state resulting in poor performance of the body and detrimental health effects.
  • Muscle wasting due to chronic diseases can lead to premature loss of mobility and increase the risk of disease-related morbidity.
  • Muscle wasting due to disuse is an especially serious problem in elderly, who may already suffer from age-related deficits in muscle function and mass, leading to permanent disability and premature death.
  • Muscle wasting includes the progressive loss of muscle mass and/or to the progressive weakening and degeneration of muscles, including the skeletal or voluntary muscles, which control movement, cardiac muscles, which control the heart (cardiomyopathies), and smooth muscles.
  • Chronic muscle wasting is a chronic condition (i.e. persisting over a long period of time) characterized by progressive loss of muscle mass, weakening and degeneration of muscle.
  • the loss of muscle mass that occurs during muscle wasting can be characterized by muscle protein degradation by catabolism.
  • Protein catabolism occurs because of an unusually high rate of protein degradation, an unusually low rate of protein synthesis, or a combination of both.
  • Muscle protein catabolism whether caused by a high degree of protein degradation or a low degree of protein synthesis, leads to a decrease in muscle mass and to muscle wasting.
  • Health status during the aging process is significantly influenced by nutrition.
  • Measures of physical performance are objective tests of a subject's performance of standardized tasks, and can be evaluated according to predetermined criteria that can include counting repetitions or timed activity.
  • a decline in physical performance results in increased odds that the subject can suffer an adverse event such as an injurious fall and/or fracture.
  • a decline in physical performance also can result in the subject having to be admitted to a nursing home and/or developing functional dependence in activities of daily living.
  • Sarcopenia has been identified as a contributor to loss in muscle functionality.
  • Muscle functionality can be a deciding criteria between deciding whether a subject can be considered sufficiently functional to live alone or if the subject requires an amount of assistance with everyday tasks that would preclude the subject from living alone.
  • Functional activities such as standing from a seated position, reaching for and retrieving an object, bending, transferring, walking and standing require muscle functionality.
  • loss of muscle mass particularly the loss of type II muscle fibers can result in diminished strength and power-generating capacity (Harris, J utr. 127: 1004S-1006S (1997))
  • loss of muscle function can more directly impact the quality of life of an elderly subject.
  • a particular effect of loss of muscle function is diminished balance in the elderly. An apparent result of this loss of balance is the frequent falls experienced by the elderly.
  • Muscle function can be assessed by any technique known in the art. These include the Berg Balance Test, functional reach tests, lateral reach tests, step tests, four square step test, elderly mobility scale tests, sensory oriented mobility assessment instrument (SOMAI) testing, Fullerton advanced balance scale, Tinetti performance orientated mobility assessment, change of direction while stepping tests, timed up and go tests, timed stand tests, clinical test of sensory interaction and balance, and hierarchical assessment of balance and mobility (e.g., see Berg, Physiotherapy Canada 41(6): 240 ⁇ 245 (1989); Bogle Thorbahn et al, Physical Therapy 76(6): 576-585 (1996) and Perell et al, The Journals of Gerontology: Series A 56(12): M761-M766 (2001)).
  • Berg Balance Test functional reach tests, lateral reach tests, step tests, four square step test, elderly mobility scale tests, sensory oriented mobility assessment instrument (SOMAI) testing, Fullerton advanced balance scale, Tinetti performance orientated mobility assessment, change of direction while stepping tests, timed up
  • Loss of skeletal muscle mass occurs with ageing. For example, in the 60 years after a person's 21 st birthday, the decline in skeletal muscle mass can be as high as 40% (Evans, J Gerontol. 50A: 147-150 (1995); Schoeller, Am J Clin Nutr. 50: 1 176-1 181 (1989)). The depletion of muscle mass does not necessarily result in weight loss in the subject because there can be a corresponding accumulation of body fat, which could mask the loss of muscle mass. The age-associated changes in muscle composition result from a combination of different factors, including a general decline in muscle protein turnover (Nair, J Gerontol
  • beta-alanine can be administered to an elderly subject in combination with a dietary protein or a protein supplement comprising a combination of amino acids.
  • the protein is a whey protein, or a whey protein isolate, a soy protein or soy protein isolate, a casein or any combination thereof.
  • the protein is fortified with one or more essential amino acids.
  • beta-alanine is administered with one or more essential amino acids, particularly leucine.
  • the beta-alanine can be administered with a combination of isolated whey proteins and isolated casein proteins.
  • the beta-alanine is co-administered with a dietary source of protein high in essential amino acids, such as beef or chicken. In some methods, the beta-alanine is co- administered with a dietary source of protein high in omega-3 fatty acids. In some methods, the beta-alanine is co-administered with a dietary source of protein and a source of omega-3 fatty acids.
  • Resistance training has been shown to be particularly successful in increasing muscle mass and strength, including in the elderly with a mean age of 90 exhibiting symptoms of frailty (Fiatarone et al, N Engl J Med. 330: 1769-1775 (1994)). It has been found that administering beta-alanine to elderly subjects allows for prolonged or increased exercise, including resistance training, by minimizing muscle fatigue as compared to exercising without beta-alanine supplementation. In the methods provided herein, the beta-alanine also can improve exercise tolerance.
  • the beta-alanine can be co-administered with, and the pharmaceutical compositions can include, other medicinal agents, pharmaceutical agents and/or adjuvants.
  • suitable medicinal and pharmaceutical agents include modulators of one or more of skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin T, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, and the skeletal sarcomere and other suitable therapeutic agents such as anti-obesity agents.
  • Exemplary medicinal and pharmaceutical agents that can be co-administered with beta-alanine include, for example: orlistat, sibramine, diethylpropion, phentermine, benzaphetamine, phendimetrazine, estrogen, estradiol, levonorgestrel, norethindrone acetate, estradiol valerate, ethinyl estradiol, norgestimate, conjugated estrogens, esterified estrogens, medroxyprogesterone acetate, testosterone, insulin-derived growth factor, human growth hormone, riluzole, cannabidiol, prednisone, albuterol and non- steroidal anti-inflammatory drugs.
  • orlistat sibramine, diethylpropion, phentermine, benzaphetamine, phendimetrazine, estrogen, estradiol, levonorgestrel, norethindrone acetate, estradiol valerate, ethin
  • Additional exemplary medicinal and pharmaceutical agents that can be coadministered with beta-alanine include TRH, diethylstilbesterol, theophylline, enkephalins, E series prostaglandins, sulbenox, growth hormone secretagogues, such as GHRP-6, GHRP-1 (disclosed in U.S. Pat. No.
  • a lipase inhibitor such as orlistat or ATL-962 (Alizyme)
  • a serotonin (and dopamine) reuptake inhibitor such as sibutramine, topiramate or axokine
  • anorectic agents such as dexamphetamine, phentermine, phenylpropanolamine or mazindol
  • an HIV or AIDS therapy such as indinavir sulfate, saquinavir, saquinavir mesylate, ritonavir, lamivudine, zidovudine, lamivudine/zidovudine combinations, zalcitabine, didanosine, stavudine, and megestrol acetate, an anti-resorptive agent, vitamin D, vitamin D analogues, and cathepsin K inhibitors.
  • the methods include co-administration of beta-alanine and vitamin D or a vitamin D analog. In some embodiments, the methods include providing at least 600 IU (15 ⁇ g) vitamin D per day. In some embodiments, the methods include providing at least 1,000 IU vitamin D per day. In some embodiments, the methods include providing at least 1,500 IU vitamin D per day. In some embodiments, the methods include providing at least 2,000 IU vitamin D per day. In some embodiments, the methods include providing at least 2,500 IU vitamin D per day. In some embodiments, the methods include providing at least 5,000 IU vitamin D per day. In some embodiments, the methods include providing at least 7,500 IU vitamin D per day. In some embodiments, the methods include providing at least 10,000 IU vitamin D per day.
  • the methods include providing at least 15,000 IU vitamin D per day. In some embodiments, the methods include providing at least 20,000 IU vitamin D per day. In some embodiments, the methods including providing between 500 and 25,000 IU vitamin D per day. In some embodiments, the methods include co-administering beta-alanine and a vitamin D or a vitamin D analog, where the amount of vitamin D or a vitamin D analog administered results in a blood serum level of 25- hydroxyvitamin D greater than 50 ng/mL, such as between 60 ng/mL to 60 ng/mL.
  • the beta-alanine also can be co-administered with creatine and/or histine.
  • the beta-alanine is co-administered with a nutraceutical.
  • the beta-alanine is co-administered with a vitamin, a mineral, an omega 3 fatty acid or combinations thereof.
  • the beta-alanine can be provided in any dosage form.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the beta-alanine can be admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch.
  • Such dosage forms also can include, as is normal practice in the pharmaceutical arts, additional substances and/or inert diluents, e.g., lubricating agents, such as magnesium stearate, buffering agents, such as sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, and calcium bicarbonate, and can include additional active ingredients.
  • Dosage forms in the form of tablets and pills can additionally be prepared with enteric coatings.
  • the dosage form is a liquid, dissolvable film or a chewable form, particularly for individuals that have a difficult time swallowing tablets or capsules.
  • the dosage form can include flavoring and/or sweetening agents.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
  • the methods provided herein include administering beta-alanine via parenteral administration.
  • Dosages for such administration can include sterile aqueous or non- aqueous solutions, suspensions, or emulsions.
  • non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
  • Such dosage forms also can contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents.
  • the formulations can be sterilized by, for example, filtration through a bacteria-retaining filter, by
  • sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They also can be manufactured in the form of sterile solid compositions, which can be dissolved in sterile water, or some other sterile injectable medium immediately prior to use.
  • the methods provided herein also include administering beta-alanine in a composition for rectal or vaginal administration, such as suppositories, which may contain, in addition to beta-alanine, excipients such as cocoa butter or a suppository wax.
  • a composition for rectal or vaginal administration such as suppositories, which may contain, in addition to beta-alanine, excipients such as cocoa butter or a suppository wax.
  • the methods provided herein also include administration of beta-alanine via nasal or sublingual administration, using formulations prepared using standard excipients that are well known in the art.
  • supplemental vitamins and/or minerals also can be administered, before, concurrent with, or after administration of the beta-alanine.
  • Suitable minerals can include one or more minerals or mineral sources with a focus on use of critical vitamins or minerals associated with benefit in the aging process. These include vitamin D, calcium, the family of B vitamins, vitamin A, E and C.
  • Non-limiting examples of minerals include, without limitation: chloride, sodium, iron, chromium, copper, iodine, zinc, magnesium, manganese, molybdenum, phosphorus, potassium, and selenium.
  • Suitable forms of any of the foregoing minerals include soluble mineral salts, slightly soluble mineral salts, insoluble mineral salts, chelated minerals, mineral complexes, non-reactive minerals such as carbonyl minerals, and reduced minerals, and combinations thereof.
  • the methods provided herein include administering vitamins in conjunction with a beta-alanine.
  • the vitamins can be fat-soluble or water soluble vitamins. Suitable vitamins include but are not limited to vitamin C, vitamin A, vitamin E, vitamin B12, vitamin K, riboflavin, niacin, vitamin D, vitamin B6, folic acid, pyridoxine, thiamine, pantothenic acid, and biotin.
  • the form of the vitamin can include salts of the vitamin, derivatives of the vitamin, compounds having the same or similar activity of a vitamin, and metabolites of a vitamin.
  • Tablets and pills can be compressed, multiply compressed, multiply layered, and/or coated.
  • the coating cab be single or multiple.
  • the coating material includes a polysaccharide or a mixture of saccharides and glycoproteins extracted from a plant, fungus, or microbe.
  • Non-limiting examples include corn starch, wheat starch, potato starch, tapioca starch, cellulose, hemicellulose, dextrans, maltodextrin, cyclodextrins, inulins, pectin, mannans, including glucomannans and galactomannans, gum arabic, locust bean gum, mesquite gum, guar gum, gum karaya, gum ghatti, tragacanth gum, carrageenans, , ⁇ -glucans, agar, alginates, chitosans, xanthan gum, rhamsan gum or gellan gum.
  • the coating material can include a protein.
  • Suitable proteins include, but are not limited to, gelatin, casein, collagen, whey proteins, soy proteins, rice protein, and corn proteins.
  • the coating material can include a fat or oil, and in particular, a high temperature melting fat or oil.
  • the fat or oil can be hydrogenated or partially hydrogenated, and can be derived from a plant.
  • the fat or oil can include glycerides, free fatty acids, fatty acid esters, or a mixture thereof.
  • the coating material contains an edible wax. Edible waxes can be derived from animals, insects, or plants. Non-limiting examples include beeswax, lanolin, bayberry wax, carnauba wax, and rice bran wax. Tablets and pills also can be prepared with enteric coatings.
  • the methods include administering beta-alanine in a controlled release or sustained release formulation.
  • the beta-alanine can be provided in a controlled release matrix, where the beta-alanine is dispersed within a matrix that can be either insoluble, soluble, or a combination thereof.
  • Controlled release matrix dosage forms of the insoluble type are also referred to as "insoluble polymer matrices”, “swellable matrices”, or “lipid matrices” depending on the components that make up the matrix.
  • Controlled release matrix dosage forms of the soluble type also are referred to as "hydrophilic colloid matrices", “erodible matrices", or “reservoir systems”.
  • Controlled release matrix dosage forms can include an insoluble matrix, a soluble matrix or a combination of insoluble and soluble matrices in which the rate of release is slower than that of an uncoated non-matrix conventional or immediate release dosage forms or uncoated normal release matrix dosage forms.
  • Controlled release matrix dosage forms can be coated with a "control-releasing coat” to further slow the release of the bupropion salt from the controlled release matrix dosage form.
  • Such coated controlled release matrix dosage forms can exhibit "modified-release", controlled-release", “sustained- release”, “extended-release”, “prolonged-release", “delayed- release” or combinations thereof of the bupropion salt.
  • the beta-alanine in the methods provided herein can be administered in any controlled release or sustained release dosage form or unit dosage form.
  • Sustained release technologies include, but are not limited to, physical systems and chemical systems.
  • Physical systems include, but are not limited to, reservoir systems with rate-controlling membranes such as encapsulation (e.g., micro- and macro-) and membrane systems; reservoir systems without rate-controlling membranes such as hollow fibers, ultra microporous cellulose triacetate, and porous polymeric substrates and foams; monolithic systems including those systems physically dissolved in non-porous, polymeric, or elastomeric matrices (e.g., non- erodible, erodible, environmental agent ingression, and degradable) and materials physically dispersed in non-porous, polymeric, or elastomeric matrices (e.g., non-erodible, erodible, environmental agent ingression, and degradable); laminated structures including reservoir layers chemically similar or dissimilar to
  • Chemical controlled release systems include, but are not limited to, chemical erosion of polymer matrices (e.g., heterogeneous or homogeneous erosion) or biological erosion of a polymer matrix (e.g., heterogeneous, or homogeneous). Hydrogels also can be used as controlled release dosage forms (e.g., see Controlled Release Systems: Fabrication
  • sustained release drug formulations include, but are not limited to, microencapsulated powders; osmotic pressure-controlled gastrointestinal delivery systems; hydrodynamic pressure-controlled
  • the methods provided herein administered beta-alanine in a sustained release system can include, e.g., an oil-microencapsulated sustained release powder dosage form that can be mixed with liquid and consumed as a drink mix beverage. See, also U.S. Pat. Nos. 5, 190,775; 6,013,286; 6,696,500; 6,756,049; 6,835,397; 6,919,372; 6,992,065; and 7,048,947.
  • the beta-alanine is administered in a dosage form that includes an immediate release component and a controlled release component.
  • an immediate release layer containing beta-alanine can be coated onto the surface of substrates in which the beta-alanine is incorporated in a controlled release matrix.
  • the immediate release portion of the beta-alanine dose can be incorporated into the gelatin capsule via inclusion of a sufficient amount of immediate release drug as a powder or granulate within the capsule.
  • the gelatin capsule itself can be coated, on the interior or the exterior, with an immediate release layer of the beta-alanine.
  • the beta-alanine can be incorporated into a food product.
  • the food product may be a snack bar, a cereal, a dessert, including a frozen dessert, a functional food, or a drink.
  • a suitable drink include, e.g., fruit juice, a fruit drink, an artificially flavored drink, an artificially sweetened drink, a carbonated beverage, a sports drink, a liquid diary or dairy-like product or a shake, such as a ready-to-drink meal replacement beverage.
  • the beta-alanine is administered in a nutrition beverage or shake, such as a complete, balanced nutrition beverage or shake, or other liquid meal replacement beverage.
  • the nutrition beverage or meal replacement beverage can be provided as a powder or granulated product which, when blended with an ingestible liquid, such as milk (e.g., cow's milk, soy milk or rice milk), juice or water, produces a highly palatable, highly nutritious instant shake or beverage.
  • an ingestible liquid such as milk (e.g., cow's milk, soy milk or rice milk), juice or water
  • the beta-alanine also can be formulated in meal supplements, in enteral nutrition products and in parenteral nutrition products (e.g., such as described in Remington: The Science and Practice of Pharmacy (Gennaro, ed., Mack Publ, Co., Easton, PA (1995)).
  • the beta-alanine also can be already mixed with an ingestible liquid and provided to a consumer already prepared and ready to consume.
  • the beverage can include omega-3 amino acids.
  • the shake or nutritional beverage can include added vitamins and/or minerals.
  • vitamins and/or minerals are now well understood.
  • a positive correlation between calcium intake and bone mass has been found across many age groups. Magnesium is well understood in its role to maintain cardiovascular health, potassium for blood pressure maintenance and zinc for overall immune health.
  • the free beta-alanine dosage can be between about 1 mg and about 200 mg per kilogram body weight, or the dose of a biological source of beta-alanine (e.g., a peptide of beta-alanine, such as carnosine, or a salt of beta-alanine) can be between about 2.5 mg and about 500 mg per kg body weight.
  • a biological source of beta-alanine e.g., a peptide of beta-alanine, such as carnosine, or a salt of beta-alanine
  • suitable dosages for an 80 kg person per day can be between 0.08 grams to 16.0 grams of free beta-alanine or an amount of a biological source of beta-alanine that provides an equivalent amount of beta ⁇ alanine.
  • the total amount of free beta-alanine administered in a controlled release dosage per day can be at least 200 mg, from 200 mg to 6.4 g, from 2.4 g to 12 g, or from 3.2 g to 16 g or more per day for a human.
  • a single dose of active ingredient, e.g., free beta-alanine or a biological source thereof, can be formulated to be in the amount about 200 mg, 400 mg, 800 mg, 1, 200 mg, 1,400 mg, 1,600 mg, 2,400 mg, 3,200 mg, 4,800 mg, 6,400 mg or more.
  • Dosage amount, interval between doses, and duration of treatment can be adjusted to achieve a desired effect.
  • dosage amount and interval between doses are adjusted to maintain a desired concentration of beta-alanine, or of increased carnosine synthesis, in a subject.
  • dosage amount and interval between doses are adjusted to provide plasma concentration of beta-alanine at an amount sufficient to achieve a desired effect, such as to increase the amount of carnosine in a muscle tissue.
  • the plasma concentration is maintained above the minimal effective concentration (MEC).
  • a therapeutically effective dosage of beta- alanine should produce a blood, plasma or serum concentration of beta-alanine or an equivalent amount of a biological source of beta-alanine to muscle or other tissue of from about 0.1 ⁇ g/ ⁇ to about 50-100 //g/ml. It has been determined that maintaining the serum levels of beta-alanine at an elevated level for a longer period of time is beneficial in the elderly.
  • the methods provided herein include administering beta-alanine with a dosage regimen designed to maintain a concentration above the MEC for 10-90% of the time, between 30-90% of the time, or between 50-90% of the time.
  • beta-alanine is administered at a dosage and over a period of time sufficient to increase muscle carnosine levels at least 10%, or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110% , at least 120% , at least 130% , at least 140% , at least 150% or more.
  • beta- alanine is administered at a dosage and over a period of time sufficient to increase muscle carnosine levels to at least 30 mmol/kg dry muscle weight, or at least 32 mmol/kg dry muscle weight, or at least 34 mmol/kg dry muscle weight, or at least 36 mmol/kg dry muscle weight, or at least 38 mmol/kg dry muscle weight, or at least 40 mmol/kg dry muscle weight, or at least 42 mmol/kg dry muscle weight, or at least 44 mmol/kg dry muscle weight, or at least 46 mmol/kg dry muscle weight, or at least 48 mmol/kg dry muscle weight, or at least 50 mmol/kg dry muscle weight, or at least 52 mmol/kg dry muscle weight, or at least 54 mmol/kg dry muscle weight, or at least 56 mmol/kg dry muscle weight, or at least 58 mmol/kg dry muscle weight, or at least 60 mmol/kg dry muscle weight, or at least 65 mmol/kg dry muscle weight, or at
  • Beta-alanine can be administered in methods to increase muscle mass, strength and physical function in a subject having or at risk of developing sarcopenia or frailty.
  • the method includes administering beta-alanine to a subject over a period of time, such as 1 week, 2 weeks, or more than 2 weeks, including 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 weeks, or for 30, 60, 90, 120, 180, 240 or more days, or for 1, 2, 3, 4, 5 or more years.
  • the beta-alanine can be administered multiple times per day, such as 2, 3, 4, 5, 6, 7, or 8 times a day, or can be formulated for sustained or controlled release such that the beta-alanine can be administered in a dosage form once, twice or three or four times daily.
  • the beta-alanine can be administered as a pharmaceutical with meals or between meals.
  • the composition containing the beta-alanine can be administered any number of times that is both feasible and effective.
  • the beta-alanine can be formulated in a food product such that it can be consumed as a part of a meal or as a snack.
  • the amount of beta-alanine per dose can be between 0.1 g and 16 g per day.
  • the beta-alanine is administered as a dosage of 200 mg, 400 mg, 600 mg, 800 mg, 1,000 mg, 1,200 mg, 1,400 mg, 1,600 mg, 1,800 mg, 2,000 mg, 2,400 mg, 2,800 mg, 3,200 mg, 4,000 mg, 4,400 mg, 4,800 mg, 5,400 mg, 5,800 mg or 6,400 mg one or more times a day.
  • the methods include administering a bolus dose or a sustained release or controlled release dosage or a combination thereof of beta-alanine to deliver a daily dosage of beta-alanine of between about 0.2 grams and 16 grams.
  • the daily dosage of beta-alanine is selected from among 200 mg, 250 mg, 400 mg, 500 mg, 600 mg, 650 mg, 750 mg, 800 mg, 1,000 mg, 1,200 mg, 1,250 mg, 1,400 mg, 1,500 mg, 1,600 mg, 1,650 mg, 1,750 mg, 1,800 mg, 2,000 mg, 2,200 mg, 2,250 mg, 2,400 mg, 2,500 mg, 2,600 mg, 2,650 mg, 2,750 mg, 2,800 mg, 3,000 mg, 3,200 mg, 3,250 mg, 3,400 mg, 3,500 mg, 3,600 mg, 3,650 mg, 3,750 mg, 3,800 mg, 4,000 mg, 4,200 mg, 4,250 mg, 4,400 mg, 4,500 mg, 4,600 mg, 4,650 mg, 4,750 mg, 4,800 mg, 5,000 mg, 5,200 mg, 5,250 mg, 5,400 mg, 5,500 mg, 5,600 mg, 5,650 mg, 5,750 mg, 5,800 mg, 6,000 mg, 6,200 mg, 6,250 mg, 6,400 mg, 6,500 mg, 6,600 mg, 6,650 mg, 6,750 mg, 6,750 mg,
  • the beta- ⁇ alanine can be administered in conjunction with exercise.
  • the beta-alanine can be administered prior to or following exercise.
  • the beta-alanine can be administered, e.g., immediately prior to or immediately after exercise.
  • the exercise include aerobic exercise.
  • the exercise includes anaerobic exercise.
  • the method includes as a step performing a resistance exercise motion.
  • the beta-alanine can improve exercise tolerance in the elderly subject and/or minimize muscle fatigue.
  • beta-alanine administered to a subject having or at risk of developing sarcopenia or frailty may stop or reverse a decline in skeletal muscle tissue mass, or muscle atrophy, when administered alone or in conjunction with exercise.
  • beta-alanine can increase muscle fitness in the elderly, alone or in combination with exercise, particularly in an elderly subject having or at risk of developing sarcopenia or frailty.
  • Administration of beta-alanine also can increase physical endurance and physical performance in the elderly, particularly an elderly subject having or at risk of developing sarcopenia or frailty.
  • elderly subjects to which the beta- alanine is administered can perform physical activities for a longer time than elderly subjects not administered beta-alanine.
  • Administration of a beta-alanine to a subject having or at risk of developing sarcopenia or frailty also can improve skeletal muscle endurance and/or resistance to fatigue.
  • Administering beta-alanine to an elderly subject can increase muscle oxidative capacity. Muscle oxidative capacity is a factor for muscle endurance and muscle fatigue resistance. Hence, this in combination with the increase in buffering capacity in muscle tissue afforded by increased carnosine synthesis upon administration of beta-alanine augments resistance to muscle fatigue in the elderly.
  • Administration of a beta-alanine to a subject having or at risk of developing sarcopenia or frailty can inhibit muscle catabolism and/or increase muscle anabolism, particularly when administering in combination with essential amino acids or with a protein source.
  • the beta-alanine is administered alone or in combination with a protein source, or in combination with one or more essential amino acids, or in combination with a protein and free essential amino acids.
  • Administration of a beta-alanine to a subject having or at risk of developing sarcopenia or frailty can improve the muscle:fat ratio in mammals including humans.
  • such methods include administering beta-alanine as a pharmaceutical dosage, dietary supplement or in the form of a foodstuff containing beta-alanine.
  • the methods can include exercise as a step.
  • the exercise can be aerobic, anaerobic or a combination thereof.
  • the methods can include modifying the diet of the subject to increase the intake of protein by the subject.
  • the method includes co-administering beta-alanine with a dietary protein, such as an animal protein (for example milk, meat, fish or egg protein), a vegetable protein (for example soy, wheat, rice, bean or pea protein), a whey protein, an isolated whey protein, a soy protein, an isolated soy protein, a casein protein, or any combination thereof.
  • a dietary protein such as an animal protein (for example milk, meat, fish or egg protein), a vegetable protein (for example soy, wheat, rice, bean or pea protein), a whey protein, an isolated whey protein, a soy protein, an isolated soy protein, a casein protein, or any combination thereof.
  • the methods include administering compositions containing one or more free essential amino acids.
  • the methods include modifying the caloric intake of the mammal by providing a diet high in protein and fiber but low in carbohydrates with a high glycemic index.
  • the fiber is soluble fiber, while in other methods, the fiber is
  • Administration of a beta-alanine to a subject having or at risk of developing sarcopenia or frailty can improve the gait of the subject, e.g., increase stride length, reduce stride frequency and/or reduce stance width variability, and also prevent, treat, delay, mitigate and/or ameliorate the onset, advancement, severity and/or symptoms of sarcopenia.
  • the increase in stride length following administration of the beta-alanine can be any increase, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% 95%, 96%, 97%, 98%, 99% or more, relative to the stride length prior to treatment with the beta-alanine.
  • the stride length following administration of the beta-alanine is greater than the standardized average stride length.
  • Also provided are methods of decreasing stride frequency in a subject having sarcopenia or susceptible of developing sarcopenia which include administering beta ⁇ alanine to the subject in an amount and for a sufficient time to decrease stride frequency.
  • the decrease in stride frequency following administration of the beta-alanine can be any decrease, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% 95%, 96%, 97%, 98%, 99% or more, relative to the stride frequency prior to treatment with the beta-alanine.
  • Also provided are methods of decreasing stride length variability in a subject having sarcopenia or susceptible of developing sarcopenia which include administering a beta- alanine to the subject in an amount and for a sufficient time to decrease stride length variability.
  • the decrease in stride length variability following administration of the beta- alanine can be any decrease, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% 95%, 96%, 97%, 98%, 99% or more, relative to the stride length variability prior to treatment with the beta-alanine.
  • the increase in hand grip strength following administration of the beta-alanine can be any increase, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% 95%, 96%, 97%, 98%, 99% or more, relative to the hand grip strength prior to treatment with the beta-alanine.
  • the method includes administering to the subject a beta-alanine in an effective amount and for sufficient time to improve the muscle
  • the methods can result improved results in the timed get-up-and- go test, the timed stand test, the stair climb muscle power test, and improvements in balance, such as the one-leg balance test or improvements in one or more criteria of the Berg balance test.
  • the method including administering to the subject a beta-alanine in an effective amount and for sufficient time to improve the Berg Balance test score of the subject compared to a baseline score prior to administration of the beta-alanine.
  • the Berg Balance test score can be improved by at least +5, and can be improved by +6, +7, +8, +9, +10, +11, +12, +13, +14, +15 or more.
  • the score is improved to be in a range between 30 and 40 or between 40 and 50.
  • the VO2 level achieved is higher than when beta-alanine is not ingested.
  • the uptake of oxygen is higher when an individual participated in an exercise regimen, as described herein, and ingested beta-alanine in the amounts described herein and for a period of time as described herein than an individual that has not ingested beta-alanine.
  • a beta-alanine can be used to prevent, treat, delay, mitigate, decrease and/or ameliorate the onset, advancement, severity and/or symptoms of sarcopenia in a subject.
  • a beta-alanine can be used to prepare a medicament to prevent, treat, delay, mitigate, decrease and/or ameliorate the onset, advancement, severity and/or symptoms of sarcopenia in a subject.
  • a beta-alanine also can be used for maintaining or increasing muscle mass and/or muscle strength and/or muscle function in a subject having or susceptible of developing sarcopenia or frailty.
  • a beta-alanine also can be used to prepare a medicament for maintaining or increasing muscle mass and/or muscle strength and/or muscle function in a subject having or susceptible of developing sarcopenia or frailty.
  • a beta-alanine also can be used to improve an appendicular skeletal muscle mass t- score of a subject, particularly in a subject having a negative appendicular skeletal muscle mass t-score (a score less than zero).
  • the appendicular skeletal muscle mass t-score of a subject can be improved by +0.5, +1, +1.5, +2, +2.5, +3 or more.
  • a beta-alanine also can be used to stop or reverse a decline in skeletal muscle tissue function in a subject having or at risk of developing sarcopenia or frailty.
  • a beta-alanine also can be used to prepare a medicament for stopping or reversing a decline in skeletal muscle tissue function in a subject having or at risk of developing sarcopenia or frailty.
  • a beta-alanine can be used to inhibit muscle catabolism and/or increase muscle anabolism in a subject having or at risk of developing sarcopenia or frailty.
  • a beta-alanine can be used to prepare a medicament for inhibiting muscle catabolism and/or increasing muscle anabolism in a subject having or at risk of developing sarcopenia or frailty.
  • a beta-alanine can be used to improve the muscle:fat ratio in a subject having or at risk of developing sarcopenia or frailty.
  • a beta-alanine can be used to prepare a medicament for improving the muscle:fat ratio in a subject having or at risk of developing sarcopenia or frailty.
  • a beta-alanine can be used to improve the gait of a subject having or at risk of developing sarcopenia or frailty.
  • improving the gait of the subject includes increasing stride length, reducing stride frequency, reducing stance width variability or a combination thereof.
  • a beta-alanine can be used to prepare a medicament for improving the gait of a subject having or at risk of developing sarcopenia or frailty.
  • a beta-alanine can be used to prevent, treat, delay, mitigate and/or ameliorate the onset, advancement, severity and/or symptoms of frailty in a subject.
  • Use of a beta-alanine can stop or reverse declines in functional reserve, reduce time to exhaustion, increase mean nominal walking speed, decrease muscle weakness and improve muscle functionality.
  • Use of a beta-alanine can also lead to sustained or increased physical activity in a subject.
  • a beta- alanine can be used to prepare a medicament to prevent, treat, delay, mitigate and/or ameliorate the onset, advancement, severity and/or symptoms of frailty in a subject.
  • a beta-alanine can be used to improve muscle functionality of a subject having or at risk of developing sarcopenia or frailty.
  • the improvement in muscle functionality can be demonstrated by a reduction in the time required to complete a timed get-up-and-go test, or by a reduction in the time required to complete a timed stand test.
  • a beta-alanine can be used to prepare a medicament to improve muscle functionality of a subject having or at risk of developing sarcopenia or frailty.
  • a beta-alanine can be used to improve a Berg Balance test score in an elderly subject.
  • a beta-alanine can improve a Berg Balance test score by at least +5.
  • a beta-alanine can improve a Berg Balance test score so that it is in a range between 30 and 40 or between 40 and 50.
  • a beta-alanine can be used to prepare a medicament to improve a Berg Balance test score in an elderly subject.
  • a beta-alanine can be used to increase hand grip strength in a subject having or susceptible of developing sarcopenia or frailty.
  • a beta-alanine can increase hand grip strength by any increment, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% 95%, 96%, 97%, 98%, 99% or more, relative to the hand grip strength prior to treatment with the beta-alanine.
  • a beta-alanine can be used to prepare a medicament to increase hand grip strength in a subject having or susceptible of developing sarcopenia or frailty.
  • a beta-alanine can be used to decrease stride frequency in a subject having sarcopenia or susceptible of developing sarcopenia.
  • the decrease in stride frequency following administration of a beta-alanine can be any decrease, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% 95%, 96%, 97%, 98%, 99% or more, relative to the stride frequency prior to treatment with the beta-alanine.
  • a beta-alanine can be used to prepare a medicament to decrease stride frequency in a subject having sarcopenia or susceptible of developing sarcopenia.
  • a beta-alanine also can be used to decrease stride length variability in a subject having sarcopenia or susceptible of developing sarcopenia.
  • the decrease in stride length variability following administration of the beta-alanine can be any decrease, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% 95%, 96%, 97%, 98%, 99% or more, relative to the stride length variability prior to treatment with the beta-alanine.
  • the amount of a beta- alanine can vary, and can be provided in a dosage effective to maintain a plasma
  • the medicaments can be formulated as unit dosages.
  • the amount of beta-alanine per unit dose can be between 100 mg and 2,000 mg, and a single unit dose can include a beta-alanine at a dose of 200 mg, 400 mg, 600 mg, 800 mg, 1,000 mg, 1,200 mg, 1,400 mg, 1,600 mg, 1,800 mg, 2,000 mg, 2,400 mg, 2,800 mg, 3,200 mg, 4,000 mg, 4,400 mg, 4,800 mg, 5,400 mg, 5,800 mg or 6,400 mg.
  • a single bolus dose of beta-alanine greater than 800 mg can result in symptoms of paraesthesia.
  • single unit doses containing greater than 800 mg of a beta-alanine can be formulated as controlled release dosages.
  • the medicament can be formulated so that it delivers a dosage of a beta-alanine over a period of 6 hours, 8 hours, 12 hours or 24 hours a total dose of a beta ⁇ alanine of between 0.1 g and 16 g per day.
  • the medicament can be formulated to deliver an amount of a beta- alanine of 200 mg, 400 mg, 600 mg, 800 mg, 1,000 mg, 1,200 mg, 1,400 mg, 1,600 mg, 1,800 mg, 2,000 mg, 2,400 mg, 2,800 mg, 3,200 mg, 4,000 mg, 4,400 mg, 4,800 mg, 5,400 mg, 5,800 mg or 6,400 mg.
  • the effect of 12 weeks of dietary supplementation with beta-alanine in elderly subjects to assess effect on exercise tolerance and muscle carnosine concentration by MRS was evaluated.
  • the treatment consisted of administering two 800 mg beta-alanine controlled release supplements 2 times per day (3.2 g beta-alanine in a 24 hour period), over the course of twelve weeks.
  • Muscle carnosine levels were measured non-invasively during this time by MRS and the effect on exercise capacity, aerobic and/or anaerobic, was assessed using a treadmill test adapted for use with elderly people and with a pre-supplementation endurance time of approximately 4 minutes.
  • "timed stands” and “timed up-and-go” tests were used to assess any changes in daily-life activity functionality. Additional testing included hand grip strength, gait measurements, including stride length, stride frequency and stance variability, V02peak and muscle to fat ratio to determine lean mass of the subject.
  • Subjects were screened using a preliminary examination by a rheumatologist to approve their competency to participate in the study. Any history of diabetes, vascular, cardiac or respiratory problems, or other underlying medical problem was compiled for each subject.
  • MRS measurements of muscle carnosine were performed on the gastrocnemius muscle at 0, 6 and 12 weeks. An exercise capacity test was performed at the same times. Each subject completed an activity questionnaire at 0, 6 and 12 weeks.
  • Muscle carnosine content was measured in vivo by ⁇ -MRS using a whole body 3.0T MRI scanner (Achieve Intera, Philips, Best, The Netherlands) and a 14 cm diameter l H- surface coil.
  • the surface coil was placed centered under the calf muscle of the left leg.
  • the scanner body coil was used to obtain conventional anatomical Tl- weighted magnetic resonance images in the three orthogonal planes.
  • Spectrum raw data then was analyzed with Java Magnetic Resonance User Interface software, and processing steps included apodization to 5Hz, Fourier transform and phase correction.
  • the carnosine signal was quantified relative to an external reference.
  • Subjects in each of the groups were assessed using physical capacity tests at 0, 6 and 12 weeks. These included exercise tests and muscle function testing.
  • the subjects were required to visit the laboratory on 2 occasions within a period of one week. At the first visit, subjects performed an incremental test on a motorized treadmill to determine the ventilatory anaerobic threshold (VAT) and V0 2peak . The subjects also were submitted to one repetition square-wave transition from rest to exercise intensity
  • Food intake was assessed at 0, 6 and 12 weeks by three 24-hour dietary recalls undertaken on separate days (2 weekdays and 1 weekend day) using a visual aid photo album of real foods.
  • the 24-hour dietary recall included the listing of foods and beverages consumed during the 24 hour period prior to the recall.
  • Energy and macronutrient intakes were analyzed using nutritional computer software (e.g., Virtual Nutri (Philippi et al, Virtual Nutri (software)— Version 1.0 for Windows. Sao Paulo: Departamento de Nutricao da Faculdade de Saiide Piiblica da Universidade de Sao Paulo, (1996)).
  • V0 2peak V0 2peak
  • VAT time-to-exhaustion were determined through VO 2 testing. Serum and urinary creatinine, proteinuria, albuminuria, liver enzymes, and hematology were assessed.
  • a blood sample for clinical biochemistry (liver, muscle, kidney function tests) and full hematology was taken at 0 and 12 weeks from all subjects.
  • a 12 lead ECG was performed on each subject at 0 and 12 weeks.
  • the highlighted line represents data from subject 6.
  • Two MRS scans presented poor quality and their respective subjects were removed from analyses.
  • Fig. 4 is a graph showing correlation between percent change in the time-to- exhaustion in the TLIM test (i.e., intensity corresponding to 75% of the difference between ventilatory threshold and V02 peak) and the percent change in the muscle carnosine content.
  • Light diamonds represent placebo-supplementation and dark diamonds represent beta- alanine-supplemented subjects.
  • Fig. 6 is a graph showing correlation between percent change in the time-to- exhaustion in the incremental test and the percent change in the muscle carnosine content. Light diamonds represent placebo-supplementation and dark diamonds represent beta- alanine-supplemented subjects.
  • Beta-alanine supplementation improved performance in the TLIM test by increasing the time-to-exhaustion at 12 weeks:
  • Beta-alanine supplementation improved performance in the incremental test by increasing the time-to-exhaustion at 12 weeks:
  • V0 2 rest 0.3+0.1 0.3 ⁇ 0.0 0.3 ⁇ 0.1 0.3 ⁇ 0.0 (L/min)
  • VO 2 oxygen consumption
  • AT anaerobic threshold
  • VT ventilatory threshold
  • RER respiratory rate exchange
  • HR heart rate
  • Glycemia (mg/dL) 109.7 114.4 + 89.0 +
  • AST aspartate amino transferase
  • ALT alanine aminotransferase
  • LDH lactate dehydrogenase
  • creatine kinase CK
  • GGT glutamyltransferase
  • the report shows that 12-weeks of beta-alanine supplementation increases the muscle carnosine content in elderly people.
  • the correlations performed in this study indicated positive associations between beta-alanine-induced muscle carnosine increase and improvements in exercise tolerance, showing that dietary supplementation with beta-alanine has a role in improving daily-physical activity and exercise capacity in elderly people.
  • Beta-alanine was administered to an active 66 year old male subject over a period of
  • the subject is an avid participant in a number of fitness activities, including fast up-hill walking, swimming and cycling, and has participated in these activities for a number of years.
  • the subject's self-assessed performance in these activities was that his performance in these activities was constant but declining slightly in recent years.
  • the subject was administered 800 mg beta-alanine formulated in a controlled release tablet 3 times daily for a period of 12 weeks.
  • the subject After 4 weeks of supplementation, the subject reported that he noticed improvements in his up-hill walking and sprint cycling activity. After about 8 weeks of supplementation, the subject reported that he experienced significant improvement in his day-to-day activities, including his sustained anaerobic athletic activities. As an example, he reported that his sustained front-crawl swimming speed improved. The subject reported that he noticed the greatest improvement in his fast up-hill walking ability. This exercise is anaerobically stressful to the gastrocnemius muscle). After 12 weeks of supplementation, without any change in training procedures or any increase in training frequency or schedules, the subject reported increases in muscle functionality, particularly in the execution of day-to-day activities. The subject reported that prior to beta-alanine supplementation, his athletic activities were consistent to slightly declining, and because the subject did not change the duration or intensity of his activities, the subject attributed the increases in athletic performance he experienced to the beta-alanine supplementation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des procédés comprenant l'administration de béta-alanine afin de traiter des troubles musculaires et d'améliorer la fonction musculaire. Parmi lesdits procédés figurent des procédés permettant le maintien de la force et de la fonction musculaire (par exemple chez les personnes âgées), l'inversion ou la prévention de la fragilité ou du déclin fonctionnel lié à l'âge chez les personnes âgées, l'inversion ou la prévention de la sarcopénie, et le traitement de la détérioration musculo-squelettique chez les personnes âgées.
PCT/US2011/048465 2010-08-20 2011-08-19 Procédés de traitement de la sarcopénie et de la fragilité WO2012024611A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40191910P 2010-08-20 2010-08-20
US61/401,919 2010-08-20
US201161503818P 2011-07-01 2011-07-01
US61/503,818 2011-07-01

Publications (1)

Publication Number Publication Date
WO2012024611A1 true WO2012024611A1 (fr) 2012-02-23

Family

ID=45605444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/048465 WO2012024611A1 (fr) 2010-08-20 2011-08-19 Procédés de traitement de la sarcopénie et de la fragilité

Country Status (1)

Country Link
WO (1) WO2012024611A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT513274A4 (de) * 2012-11-02 2014-03-15 Lukas Lenhart Nahrungsergänzungsmittel
WO2014117176A1 (fr) * 2013-01-28 2014-07-31 Lopez Hector L Procédés d'amélioration de la tolérance à β-alanine, de sa pharmacodynamie et de son efficacité et son utilisation
WO2014200332A1 (fr) 2013-06-10 2014-12-18 N.V. Nutricia Conservation des muscles chez des adultes en surpoids ou obèses pendant un programme de perte de poids
WO2015048340A3 (fr) * 2013-09-25 2015-10-08 Pronutria, Inc. Compositions et formulations pour le traitement des maladies de malabsorption et les affections inflammatoires des voies gastro-intestinales, leurs procédés de production et d'utilisation
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
US9827217B2 (en) 2015-08-25 2017-11-28 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US9884813B1 (en) 2017-03-01 2018-02-06 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US9907331B2 (en) 2013-03-08 2018-03-06 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
US9943525B2 (en) 2014-10-06 2018-04-17 Samsung Electronics Co., Ltd. Composition for reducing cell senescence comprising Rho-kinase inhibitor and use thereof
WO2018091564A1 (fr) * 2016-11-16 2018-05-24 Fresenius Kabi Deutschland Gmbh Composition nutritionnelle destinée à être utilisée en thérapie de patients atteints de sarcopénie et/ou de fragilité ou de patients pré-sarcopéniques et/ou pré-fragiles
US10045999B2 (en) 2010-07-07 2018-08-14 N. V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
CN108455575A (zh) * 2018-02-19 2018-08-28 桂林理工大学 一种还原石墨烯的制备方法
WO2020092451A1 (fr) * 2018-10-29 2020-05-07 Keto Patent Group, Inc. Administration à l'homme de butyrate, de bêta-hydroxybutyrate, de cannabidiol et de composés apparentés
US20200390793A1 (en) * 2017-11-21 2020-12-17 Societe Des Produits Nestle S.A. Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass
CN114558104A (zh) * 2020-11-27 2022-05-31 利统股份有限公司 用于治疗抽筋和痉挛的配制物
US11684074B2 (en) 2017-05-12 2023-06-27 Axiom Foods, Inc. Rice products and systems and methods for making thereof
US11969411B2 (en) 2016-04-19 2024-04-30 Axcess Global Sciences, Llc Administration of berberine metabolites
US12011427B2 (en) 2019-12-11 2024-06-18 Inspirna, Inc. Methods of treating cancer
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12128020B2 (en) 2024-02-29 2024-10-29 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080242727A1 (en) * 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
US20090181903A1 (en) * 2008-01-11 2009-07-16 Robert Wolfe Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080242727A1 (en) * 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
US20090181903A1 (en) * 2008-01-11 2009-07-16 Robert Wolfe Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STEFFEN ET AL.: "Age- and Gender-Related Test Performance in Community-Dwelling Elderly People: Six-Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and Gait Speeds", PHYSICAL THERAPY, vol. 82, no. 2, February 2002 (2002-02-01), pages 128 - .137 *
STOUT ET AL.: "The effect of beta-alanine supplementation on neuromuscular fatigue in elderly (55-92 Years): a double-blind randomized study.", J INT SOC SPORTS NUTR, vol. 5, no. 21, 7 November 2008 (2008-11-07), pages 1 - 6 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045999B2 (en) 2010-07-07 2018-08-14 N. V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
AT513274B1 (de) * 2012-11-02 2014-03-15 Lukas Lenhart Nahrungsergänzungsmittel
AT513274A4 (de) * 2012-11-02 2014-03-15 Lukas Lenhart Nahrungsergänzungsmittel
WO2014117176A1 (fr) * 2013-01-28 2014-07-31 Lopez Hector L Procédés d'amélioration de la tolérance à β-alanine, de sa pharmacodynamie et de son efficacité et son utilisation
US20160271260A1 (en) * 2013-01-28 2016-09-22 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of beta-alanine and use therefor
US10130715B2 (en) 2013-01-28 2018-11-20 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of β-alanine and use therefor
US10251415B2 (en) 2013-03-08 2019-04-09 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
US9907331B2 (en) 2013-03-08 2018-03-06 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
US9961932B2 (en) 2013-06-10 2018-05-08 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
WO2014200332A1 (fr) 2013-06-10 2014-12-18 N.V. Nutricia Conservation des muscles chez des adultes en surpoids ou obèses pendant un programme de perte de poids
US9878004B2 (en) 2013-09-25 2018-01-30 Axcella Health Inc. Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof
WO2015048340A3 (fr) * 2013-09-25 2015-10-08 Pronutria, Inc. Compositions et formulations pour le traitement des maladies de malabsorption et les affections inflammatoires des voies gastro-intestinales, leurs procédés de production et d'utilisation
US11357824B2 (en) 2013-09-25 2022-06-14 Axcella Health Inc. Nutritive polypeptides and formulations thereof, and methods of production and use thereof
US10463711B2 (en) 2013-09-25 2019-11-05 Axcella Health Inc. Nutritive polypeptides and formulations thereof, and methods of production and use thereof
EP3006028B1 (fr) * 2014-10-06 2020-01-15 Samsung Electronics Co., Ltd Composition permettant la réduction de la sénescence cellulaire comprenant un inhibiteur de rho-kinase et son utilisation
US9943525B2 (en) 2014-10-06 2018-04-17 Samsung Electronics Co., Ltd. Composition for reducing cell senescence comprising Rho-kinase inhibitor and use thereof
US9827217B2 (en) 2015-08-25 2017-11-28 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US10512623B2 (en) 2015-08-25 2019-12-24 Rgenix, Inc. Pharmaceutically acceptable salts of B-Guanidinopropionic acid with improved properties and uses thereof
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11969411B2 (en) 2016-04-19 2024-04-30 Axcess Global Sciences, Llc Administration of berberine metabolites
US11612578B2 (en) 2016-11-16 2023-03-28 Fresenius Kabi Deutschland Gmbh Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients
EP3711493A1 (fr) * 2016-11-16 2020-09-23 Fresenius Kabi Deutschland GmbH Composition nutritionnelle à utiliser dans la thérapie de patients atteints de fragilité et/ou de sarcopénie ou de pré-sarcopénie ou de fragilité précoce
CN109982585A (zh) * 2016-11-16 2019-07-05 费森尤斯卡比德国有限公司 用于患有肌少症和/或衰弱症的患者或肌少症前期和/或衰弱症前期患者的疗法中的用途的营养组合物
CN109982585B (zh) * 2016-11-16 2024-03-15 费森尤斯卡比德国有限公司 用于患有肌少症和/或衰弱症的患者或肌少症前期和/或衰弱症前期患者的疗法中的用途的营养组合物
WO2018091564A1 (fr) * 2016-11-16 2018-05-24 Fresenius Kabi Deutschland Gmbh Composition nutritionnelle destinée à être utilisée en thérapie de patients atteints de sarcopénie et/ou de fragilité ou de patients pré-sarcopéniques et/ou pré-fragiles
US9884813B1 (en) 2017-03-01 2018-02-06 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US11684074B2 (en) 2017-05-12 2023-06-27 Axiom Foods, Inc. Rice products and systems and methods for making thereof
US20200390793A1 (en) * 2017-11-21 2020-12-17 Societe Des Produits Nestle S.A. Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass
CN108455575A (zh) * 2018-02-19 2018-08-28 桂林理工大学 一种还原石墨烯的制备方法
WO2020092451A1 (fr) * 2018-10-29 2020-05-07 Keto Patent Group, Inc. Administration à l'homme de butyrate, de bêta-hydroxybutyrate, de cannabidiol et de composés apparentés
US12011427B2 (en) 2019-12-11 2024-06-18 Inspirna, Inc. Methods of treating cancer
CN114558104A (zh) * 2020-11-27 2022-05-31 利统股份有限公司 用于治疗抽筋和痉挛的配制物
US12128020B2 (en) 2024-02-29 2024-10-29 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans

Similar Documents

Publication Publication Date Title
WO2012024611A1 (fr) Procédés de traitement de la sarcopénie et de la fragilité
Blancquaert et al. Effects of Histidine andA-alanine Supplementation on Human Muscle Carnosine Storage
Paddon-Jones et al. Exogenous amino acids stimulate human muscle anabolism without interfering with the response to mixed meal ingestion
US20220211750A1 (en) Compositions and methods using a combination of calcium and at least one of oleuropein or metabolite thereof
US20210023096A1 (en) Nutritional Intervention for Improving Muscular Function and Strength
US20100280123A1 (en) Food supplement containing alpha-keto acids for supporting diabetes therapy
EP3021690B1 (fr) Conservation des muscles chez des adultes en surpoids ou obèses pendant un programme de perte de poids
JP2006522821A (ja) 組織における無酸素性作業能力を高めるための方法及び組成物
US20230131476A1 (en) Compositions containing amino acids and methods of using such compositions for treating sarcopenia
US11173167B2 (en) Nutritional intervention for improving muscular function and strength
Serafini et al. Nutritional approach to sarcopenia
Mor et al. The effect of whey protein supplementation on exercise-induced muscle damage
US20210393559A1 (en) Compositions and Methods of Use of Beta-Hydroxy-Beta-methylbutyrate (HMB) for Improving Muscle Mass, Strength and Muscular Function Without Exercise
US20210113501A1 (en) Method of administering beta-hydroxy-beta-methylbutyrate (hmb)
US20230390262A1 (en) Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for treating sarcopenia and frailty
AU2023272278A1 (en) Compositions comprising a combination of creatine and oleuropein or a metabolite thereof and their use for improving muscle function
Greenwood et al. Effective nutritional supplement combinations
Smith et al. 9 Purported Ergogenic Aids
Landis et al. 9 Nitrogenous Compounds
JP2010150263A (ja) 組織における無酸素性作業能力を高めるための方法及び組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11818844

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11818844

Country of ref document: EP

Kind code of ref document: A1